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Abstract 
 
The balance between cell survival and death is a crucial process in human 
development and tissue homeostasis, but is also misregulated in disease.  In large part, 
apoptosis is controlled by caspases, a hierarchical series of cysteine aspartic acid 
proteases that demolish the cell by cleaving key structural and enzymatic proteins, but 
emerging paradigms have highlighted the ability of kinases to regulate caspase activity.  
One way in which kinases can control the progression of apoptosis is through 
phosphorylation of caspase substrates, which acts to prevent caspase cleavage of that 
target.  
In this thesis, we develop new strategies to study this regulatory mechanism, and 
focus particularly on protein kinase CK2; a kinase with enigmatic regulation, an obvious, 
but undefined role in anti-apoptotic signaling, and demonstrated value as a candidate for 
targeted therapy of cancer.  First, we used predictive strategies for identifying CK2 
substrates that, when phosphorylated, regulate proteolysis by caspases.  We predicted and 
validated that phosphorylation of caspase-3 itself by CK2 prevents its cleavage and 
activation, representing a putative, novel mechanism by which CK2 might control 
apoptosis in disease.  We then utilized cell models that over-expressed different forms of 
CK2, and found that caspase-3 phosphorylation was specific only for the CK2!" subunit 
in the absence of CK2# - a level of isozyme specificity not before seen for CK2.  
Interestingly, documented misregulation of this isoform in disease suggests that the 
phenotypes generated by varied CK2 levels in cancer may well depend on the form of 
CK2 present.  We also establish the utility of proteomic applications for identifying novel 
caspase substrates whose cleavage is regulated by phosphorylation.  We noted that 
phosphorylation can also promote caspase substrate cleavage, likely through a 
mechanism in which phosphorylation alters scissile bond accessibility.    
Collectively, our work provides insight into the regulation of protein kinase CK2 
and demonstrates that the specialized functions of different forms may define cellular 
phenotypes in disease.  Furthermore, we identified a number of caspase substrates whose 
! """!
cleavage is regulated by phosphorylation, thereby validating our novel approaches and 
delineating putative apoptotic control points. 
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CHAPTER 1 - INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Phosphorylation by protein kinases is an imperative process that orchestrates a 
number of cellular pathways (1).  Via the transfer of phosphate from ATP to protein 
substrates, kinases mediate changes in transcription, protein structure and function and 
protein-protein interactions in response to diverse stimuli.  Not surprisingly, the 
misregulation of kinases by overexpression, constitutive activation, or deactivation, can 
distort normal signaling events and lead to a diseased state.  In light of these 
observations, protein kinases have emerged as promising candidates for targeted 
therapeutics to treat a wide variety of diseases, including cancer (2). The recent success 
of Imatinib – a specific inhibitor of the bcr-abl kinase found in chronic myelogenous 
leukemia – represents the most prominent example of a kinase inhibitor impacting 
disease management in the clinic (3).  While Imatinib represents a ‘silver bullet’ for one 
specific form of cancer, these diseases remain remarkably heterogeneous – a fact 
highlighted by the multitude of kinases known to play a role in a number of other 
malignancies (2,4). 
As well as contributing to diverse aspects of signaling that ultimately promote 
cellular fitness, a specific, direct function for protein phosphorylation in regulating 
apoptotic machinery is emerging (5,6)).  Apoptosis, or programmed cell death, is a vital 
process that contributes to tissue homeostasis and development, but is often blunted in 
cancer (7).  By avoiding apoptosis, malignant cells can persist inappropriately, thereby 
contributing to tumour progression (8).  Major effectors of the apoptotic program are a 
family of proteases known as caspases.  Once activated, they function by cleaving 
 2 
structural, enzymatic and transcription factor proteins that collectively participate in the 
co-ordinated demolition of the cell (9).  Interestingly, cross-talk between protein kinases 
and caspases has become apparent, with a growing number of examples highlighting how 
kinases alter caspase activity and vice versa (reviewed in (5,6).  It is anticipated that 
understanding the convergence of these enzymes, especially in the context of the disease 
state, will benefit how the apoptotic pathway can be selectively activated in cancer cells.   
Perhaps the most pertinent kinase implicated in the regulation of caspase 
pathways is protein kinase CK2.  CK2 phosphorylates a number of caspases, caspase 
substrates, and caspase regulators (reviewed in (6,10) and 1.5 and 1.6 of this thesis).  It is 
also overexpressed in a number of human cancers, and after pharmacologically inhibiting 
CK2 in disease models of CK2 overexpression, these same cells undergo programmed 
cell death (reviewed in (10,11) and 1.4.2 of this thesis).   As such, CK2 has emerged as a 
candidate for molecular targeted therapy.  Indeed, the number of patents for CK2 
inhibitors has dramatically increased over recent years, and one, CX-4945, has even 
entered human clinical trials (12,13).  Functionally, CK2 is constitutively active, and so 
over-expression in disease is believed to promote survival by hyper-phosphorylating its 
substrates; alternatively, high levels of CK2 may also lead to inappropriate 
phosphorylation of disease-specific substrates (11).  However, gaps in our knowledge 
remain as to which substrates promote the anti-apoptotic phenotype emanating from 
CK2, and how this constitutively active kinase is regulated in cells. 
 
1.2 ENZYMATIC AND STRUCTURAL FEATURES OF CK2 
1.2.1 General 
 3 
Protein kinase CK2 was isolated almost 60 years ago on the basis of its ability to 
phosphorylate the milk protein casein (14).  As a result, it was originally designated 
'Casein kinase II', though this misnomer is less frequently used because of the lack of 
physiological significance for the phosphorylation of casein by CK2 (15). CK2 is 
ubiquitously expressed in eukaryotes, and in humans, is composed of a regulatory CK2! 
subunit and two catalytic subunits (CK2" and CK2"') (16).  Catalytically, CK2 catalyzes 
the phosphorylation of Ser/Thr and even Tyr, albeit at much lower efficiency (17-19), 
when surrounded by acidic amino acids.  Acidic residues, typically Glu or Asp at n+3 
and, to a lesser extent, n+1 are the strongest determinants, though catalysis is generally 
improved upon addition of more acidic residues (20-23).  CK2" and "' are roughly 85% 
identifical within their catalytic domains but are encoded by distinct gene products 
(16,24-26) (Figure 1.1). The only considerable divergence in sequence between the two 
catalytic subunits is located outside the catalytic domain on the C-terminus; presumably, 
this results in the inability to distinguish CK2! and !" on the basis of their catalytic 
properties (16,27).  Along these lines, there is no known substrate that displays 
preference for one catalytic subunit over the other, at least in vitro, as the residues 
dictating primary amino acid specificity are conserved (28). 
The regulatory CK2! subunit is a 25 kDa protein in humans that has little 
sequence homology with any other protein, but is extremely conserved between species 
(29,30).  Within the CK2 tetramer, or holoenzyme, CK2# forms a dimer core that is 
flanked by the two catalytic subunits (31-33).  While the protein interaction interface 
between CK2# and the catalytic subunits are considered small at 830 Å2 (33,34), the 
dissociation constants are quite strong (35); evidence for this is provided by the fact that  
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Figure 1.1 – Schematic representation of CK2! and !".  The N-terminal, catalytic and C-
terminal sections of the catalytic isoforms and their percent identity are shown.  This 
figure is a modified version from (233). 
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breaking the interaction in vitro is only possible under denaturing conditions (36).  
Although some of the enzymatic characteristics of tetrameric CK2 can be distinguished 
from that of the free catalytic subunits (discussed below), a striking feature of CK2 is that 
both of these forms are catalytically competent (27,37).  In this respect, CK2 is distinct 
from cyclin-dependent kinases where catalytic activity is dependent on the presence of an 
activating cyclin and from second messenger-dependent kinases, such as PKA, where 
catalytic activity is suppressed by an autoinhibitory subunit (38).  
 
1.2.2 Structural Features 
Structural studies have yielded many insights into the unique features of protein 
kinase CK2 (reviewed in (39)), the most important of which is the apparent active 
conformation in over 40 crystal structures to date.  This is in contrast to MAPKs and 
tyrosine kinases, for example, where activation loop phosphorylation is required to 
achieve the open confirmation and catalytic activity (40).  Structures of CK2, however, 
show the activation loop stabilized in the open confirmation in the absence of both 
regulatory phosphorylations and subunits (Figure 1.2).  In large part, this is achieved by 
stabilizing forces exerted by hydrophobic interactions between the N-terminus and the 
activation loop (36).  Furthermore, CK2 contains a ‘DWG’ motif just upstream of the 
activation loop that provides an extra hydrogen bond compared to most other kinases’ 
‘DFG’ motif (41). 
Structures of CK2 in complex with purine analogues have also revealed unique 
features of its ATP binding domain in relation to the ATP binding domain of other 
protein kinases.  In CK2, the ATP binding domain is collapsed and relatively thin in one  
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Figure 1.2 – Crystal Structure of CK2!.  Recombinant maize CK2! is shown in complex 
with Mg2+ and the ATP analogue AMPPNP (Adenylyl-imidodiphosphate) (PDB: 
1DAW).  The activation loop is shown in black and AMPPNP in blue. 
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plane, while being wider in the second plane (42).  The widening allows for the 
utilization of GTP as a phosphate donor, a relatively unique characteristic amongst 
protein kinases, while the thinning in the other plane provides the opportunity for the 
rational design of specific, small molecule ATP competitive inhibitors that exploit Van 
der Waals interactions in CK2 (43,44).  In large part, the ‘thinness’ is mediated by V66 
and I174 in CK2! – residues typically occupied by smaller amino acids in other protein 
kinases (45).  Mutation of V66 and I174 to alanine results in at least a 10-fold decrease in 
sensitivity to competitive inhibitors, offering a strategy for rescue experiments in cell 
culture systems (45,46). 
Another unique feature of CK2 revealed by cryostallography was that the 
tetrameric configuration of the holoenzyme consists of a CK2" dimer core that is flanked 
and bound by two individual catalytic subunits (33).  More recently, Lolli et al. (2012) 
demonstrate that the CK2!2/CK2"2 holoenzyme is capable of forming inactive, 
supramolecular structures composed of 3 holoenzymes (47).  In this instance, the N-
terminus from one CK2" subunit and the C-terminus from another preclude the active 
site from substrate and nucleotide binding, while the other three catalytic subunits are 
sterically hindered.  The observation that CK2 tetramers can form filamentous structures 
under crystallization conditions may clarify the finding that in cells, CK2! and " belong 
to both fast and slow moving subpopulations (48). 
CK2!# structures of the catalytic subunit have begun to highlight isozymic 
differences between the two catalytic subunits.  Bischoff et al. (2011) noted that the 
interdomain hinge region of CK2!# aligns seamlessly with the tetrameric form of CK2!, 
whereas this region of CK2! in the absence of " is slightly collapsed and may interfere 
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with productive nucleotide binding (49).  The CK2! interface of CK2" is also quite 
malleable and changes upon addition of the regulatory subunit.  Curiously, the ! interface 
on CK2"# resembles the holoenzyme form of CK2", offering an attractive explanation 
for the observed 12-fold lower of affinity of CK2"# for ! compared to " and ! (49).  
Along these lines, gel filtration of CK2"# holoenzyme suggests that CK2"# 
predominately forms trimers consisting of one catalytic subunit and a dimer of CK2!, in 
contrast to the tetramers of CK2"/! (50).   
 
1.2.3 CK2!  regulatory subunit: a modulator of CK2 function 
While CK2! is not strictly required to turn on or off the catalytic activity of CK2, 
the regulatory subunit appears to increase activity toward most substrates by enhancing 
thermal stability (typically 3-5 fold) (27,37).  Along these lines, the majority of CK2 
substrates can be effectively phosphorylated by either tetrameric CK2 or free catalytic 
CK2 subunits, but there are isolated examples of targets, such as eIF2!, where CK2! is 
required to enable efficient phosphorylation, or calmodulin, where the presence of CK2! 
leads to complete inhibition of phosphorylation (51-53).  In instances where CK2! 
stimulates phosphorylation, there is evidence to suggest that it serves as a substrate 
docking protein (34); topoisomerase II and p53 both bind CK2! at its N-terminus 
independent of the catalytic subunit (54,55).  Interestingly, in cases where CK2! blocks 
substrate phosphorylation, this can be rescued by treating the holoenzyme with 
polyamines (56).  Polyamines act to bind CK2! at amino acids 55-64 – a particularly 
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acidic stretch (DLEPDEELED) – and, it is hypothesized, compete ! away from a basic 
region of CK2" effectively widening the substrate-binding region of CK2" (57,58).   
The role of the regulatory CK2! subunit in controlling substrate specificity in 
cells remains poorly understood, mostly because of the lack of a bona fide model system 
that exhibits clear pools of catalytic subunits of CK2 not bound to CK2!.  The 
demonstration that calmodulin is phosphorylated at its CK2 sites in rat liver was amongst 
the first evidence provided to suggest that in cells, either functional free catalytic subunits 
exist, cellular holoenzyme is activated by polyamines and/or some other mechanism 
contributes to modulating CK2 substrate specificity (59).  Since this time, a number of 
other anecdotal examples have emerged.  For instance, CK2"# can be separated from 
CK2! during ion-exchange of LNCaP cell lysates, suggesting the existence of catalytic 
CK2 devoid of the regulatory subunit.  Further evidence for this form of CK2 was 
obtained when Vilk et al. (2001) observed an increase in CK2 activity upon ectopic 
expression of CK2! in U2-OS cells (60).  The authors utilized a substrate peptide with a 
moderate preference for the holoenzyme form of CK2, and so they conclude that the 
over-expressed CK2! complexed catalytic CK2 previously not apart of the holoenzyme, 
thereby raising the measured activity.  Similarly, Miyata and Nishida (2008) show that 
cdc37 phosphorylation is increased at a specific CK2 phosphorylation site upon ectopic 
expression of CK2! (61), and so is open to the same interpretation made by Vilk and 
colleagues.  On the flip side, the Pinna group observed that in CHO cell lysates, ectopic 
expression of CK2! did not alter CK2 activity against a peptide substrate specific for the 
holoenzyme (62).  The authors’ interpretation was that had free-catalytic CK2" or "# 
existed, ectopic ! would have quenched this population and been detected in lysate 
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kinase assays with the holoenzyme specific peptide.  In this respect, Luscher and 
Litchfield noted that CK2! is synthesized in excess of the catalytic subunits in lymphoma 
cells and is quantitatively incorporated into the holoenzyme (63).  Presumably, given the 
extremely tight interaction between the regulatory and catalytic subunits (KD values of 
45.5 " 10-9 M for CK2#$ and 3.7 " 10-9 M for CK2# (35)), these latter observations 
suggest that unless as of yet unknown cellular mechanisms act to segregate ! from # and 
#$, the holoenzyme will form.  Interestingly, the Filhol group has observed fluctuating 
ratios of catalytic to regulatory CK2 subunits across a panel of breast cancer tissues and a 
correlation between low CK2! levels and epithelial-to-mesenchymal transition (64).  The 
authors hypothesize that a dip in holoenzyme activity reduces phosphorylation of the 
holoenzyme-specific substrate SNAIL, which then drives the EMT (epithelial-
mesenchymal transition) phenotype.  This last example is the first hint that variations in 
the free-catalytic to holoenzyme ratio can control a cellular phenotype. 
To further study CK2!-independent functions of the catalytic subunits, new tools 
are emerging.  Raaf and colleagues have utilized the crystal structure of the CK2 
holoenzyme to rationally design mutants of CK2# that are deficient in binding to CK2!, 
though experiments exploring cellular phenotypes and substrates have not yet been 
performed (65).  Furthermore, the Cochet group has designed short peptides and low-
molecular weight chemicals that interfere with the holoenzyme formation of recombinant 
CK2 subunits (66,67).  As well, French et al. (2007) have designed a CK2! mutant 
resistant to proteasomal degradation (68).  Coupled with the fact that there is no known 
cellular mechanism for dis-assembly of the CK2 holoenzyme, extending the CK2! half-
life may increase the proportion of catalytic CK2 bound to !. 
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Holoenzyme formation also appears to alter CK2 localization. Expression of 
GFP-CK2! is almost completely nuclear, but co-expression of GFP-CK2! and YFP-
CK2" resulted in an even distribution of CK2 throughout the cell (69).  Similar 
experiments have yet to be performed with CK2!#, but both isoforms have an identical 
nuclear localization signal, suggesting similar behavior might be expected(15).  While 
CK2!# has not been studied with fluorescent fusions, defective spermatogenesis in 
CK2!#-null mice has prompted localization studies of endogenous CK2!# in testes (70).  
CK2!# localization measured in a number of testes cell types across the rat life cycle 
revealed that localization depends on age and cell type (71).  CK2!# and " are nuclear in 
the Sertoli cells of 5-day old rats, but cytoplasmic in the same cells of older rats.  Also, 
CK2!# occupies a distinct cellular location from CK2" in epididymal spermatocytes; !# 
is found predominately in the acrosome and " in the flagellum.   
Collectively, these findings suggest that CK2" controls the substrate specificity of 
CK2, but also raise the specter that individual CK2 subunits exist outside the holoenzyme 
and are governed by unique modes of regulation.  At this point however, the precise 
mechanisms that drive tetramer formation and dissociation in cells remain unclear.  
Furthermore, some of the evidence is acquired through low-resolution techniques, such as 
those performing kinases assays with cell lysates and CK2-form specific substrate 
peptides.  Here, the field would be better served with phospho-specific antibodies 
targeted against CK2-form specific substrates that aim to measure cellular CK2, though 
no such materials exist.  
 
1.3 PHYSIOLOGICAL REGULATION OF CK2 
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1.3.1 Overview of CK2 regulation 
 CK2 is accredited with the phosphorylation of a large number of proteins; 
estimates comparing a CK2 motif, or ‘weblogo’, and the known human phospho-
proteome suggest approximately 20% of known phosphorylation sites conform to the 
CK2 consensus motif (72).  Fittingly, CK2 has been implicated in a diverse set of 
functions, including development, cell cycle progression, circadian rhythms, viral 
infection, DNA damage response, autophagy and apoptosis.  Given the diversity of 
biological processes CK2 is associated with, it is not unexpected that the regulation of 
CK2 is complex and incompletely defined.  The prevalence of CK2 substrates in various 
cellular compartments, including the nucleus, cytoplasm, mitochondria and plasma 
membrane, has led to the prevailing notion that discrete populations of CK2 are 
ultimately controlled by the regulated accessibility to the substrates (73).  Furthermore, 
emerging evidence is beginning to highlight divergent roles for the catalytic isozymes; a 
function usually, but not exclusively, attributed to their divergent C-terminus. 
 
1.3.2 Catalytic isozyme specific functions 
 Despite extensive sequence similarity and catalytically identical characteristics in 
vitro, CK2! and !" appear to have unique physiological functions.  Isozyme specific 
functions have been observed in lower eukaryotes, such as Saccharomyces cerevisiae.  
Temperature sensitive alleles of CKA1 and CKA2 – the two catalytic isoforms of yeast 
CK2 – grown at the non-permissive temperature exhibit defects in cell polarity and cell 
cycle arrest, respectively (74,75).  Unique phenotypes are also observed in knockout-
mice.  CK2!" knockouts exhibit defective spermatogenesis due to increased apoptosis, 
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suggesting that CK2! is unable to compensate for this function (70).  Likewise, CK2! 
knockout mice are embryonic lethal and abort at day E11.5 (76).  As well, forced 
expression of kinase-inactive CK2!", but not inactive CK2!, contributes to a 
proliferative defect in U2-OS cells.  Collectively, these data reinforce the notion that the 
catalytic isoforms of CK2 occupy distinct nodes in signaling. 
The most obvious explanation for functional divergence of the two catalytic 
subunits is the completely unrelated C-terminus of CK2! (amino acids 330-391) (Figure 
1.1).  Interestingly, within this tail region are four proline-directed phospho-acceptors 
whose phosphorylation during prophase and metaphase is required for cell survival 
through mitosis (77).  These phosphorylation sites generate a binding module for Pin1, 
which targets CK2! to the mitotic spindle (78,79).  Furthermore, Pin1 binding to CK2! 
can alter substrate specificity (80), most notably towards topoisomerase II (78).  
Similarly, a recent role for the ERK-mediated phosphorylation of two of these sites, T360 
and S362, has been proposed to function in promoting !-catenin phosphorylation by CK2 
in an EGF-dependent manner (81).  CK2!" also has a unique substrate in the nuclear 
transcription factor NKX3.1 (82).  Using in-gel kinase assays, the Bieberich group 
demonstrated that only CK2!" fractions devoid of CK2# phosphorylate NKX3.1 and that 
phosphorylation may increase the half-life of this tumour suppressor in cell line models 
of prostate cancer.   
 The catalytic domain of CK2 also controls specific functions of the different 
isozymes.  Under the presumption that specific interacting proteins control unique roles 
for ! and !", Bosc et al. (2000) performed yeast two-hybrid screens to identify interactors 
of CK2 (83).  CKIP-1 (CK2 interacting protein-1) is a PH-domain containing protein that 
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localizes CK2!, but not CK2!", to the plasma membrane (83,84).  Changes in the 
expression of CKIP-1 induce alterations in cell morphology and the actin cytoskeleton 
(85).  Since CKIP-1 interacts with CP! (actin capping protein subunit !), a subunit of the 
heterodimeric actin capping protein that can be phosphorylated by CK2, these 
observations are consistent with a working model suggesting that CKIP-1 could 
participate in the regulation of the actin cytoskeleton by modulating the CK2 catalyzed 
phosphorylation of CP!.  Interestingly, C-terminal ! truncations (ie CK2!1-330) are just 
as able to interact with CKIP-1 as wild-type !, suggesting that specific interactions are 
guided by residues within the highly conserved region of ! and !", though the structural 
or sequence determinants that dictate specific binding remain elusive (83,86).  PP2A is 
another cytoplasmic substrate that, like CKIP-1, interacts with CK2! at regions located 
within the catalytic domain (87).  Here, interactions are governed by 176HEHRKL181, 
which is a region slightly divergent in CK2!" (HQQKKL) and, therefore may dictate 
isoform specific interactions, though this has not been rigourously tested.  Furthermore, 
because CK2!/PP2A interactions only occur in the absence of CK2#, the observation 
that endogenous CK2! and PP2A interact supports the hypothesis that CK2 has distinct, 
non-holoenzymatic functions within the cell. 
 CK2! and !" also differ in their subcellular localization.  Despite identical 
nuclear localization signals (15), Brown et al. (2010) observed an high CK2!:CK2!" 
ratio in the nucleus and low ratio in the cytoplasm of head and neck squamous cell 
carcinoma cell lines(88).  Further supporting differential mechanisms that control 
localization is the finding that CK2!", but not !, shuttles to the nucleus in response to 
ioinizing radiation in HeLa cells (89).  The molecular mechanisms controlling re-
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localization in this case remain enigmatic.  What is interesting, though, is that CK2! 
appears to control nuclear localization of CK2"; expression of GFP-CK2" (green 
fluorescent protein-CK2 fusion) is almost completely nuclear in HeLa cells, but co-
expression of GFP-CK2" and YFP-CK2! (yellow fluorescent protein-CK2 fusion) 
resulted in an even distribution of CK2 throughout the cell (69).  Furthermore, a small 
population of yeast CK2A2 dissociate from CK2! after UV stress, perhaps supporting a 
mechanism by which CK2! is a controller of nuclear CK2"# in response to DNA damage 
(90).   
 
1.3.3 CK2 in cell stress 
Functionally, the phosphorylation of CK2 substrates has implications in 
controlling diverse cellular events.  For instance, CK2 is an emerging, major player in the 
DNA damage response.  CK2 constitutively phosphorylates XRCC1 (X-ray repair cross-
complementing protein 1) (91,92) and MDC1 (93), which generates binding sites for 
FHA (fork-head associated) domains, and increases cell survivability after DNA damage 
(94).  Evidence for CK2 stimulation after DNA damage has also been observed.  
Phospho-proteomics experiments investigating kinase activity after double-stranded 
DNA breaks noted an increase in the number of phospho-peptides containing sequences 
that conform to the CK2 consensus motif (95).  One specific substrate that is dynamically 
controlled after DNA damage is HP!-1 as phosphorylation occurs within seconds of 
double stranded breaks (96).  After phosphorylation, HP!-1 is mobilized and the 
recruitment of other proteins, such as $-H2AX, to sites of DNA damage is promoted.  In 
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both the phospho-proteomic and HP!-1 study, how CK2 activity is stimulated remains 
elusive.   
Mechanistic explanations for the control of CK2 activity against other substrates 
are beginning to emerge.  After exposing HeLa cells to UV radiation, NF-"B induction is 
blocked by either CK2! knockdown or alanine mutations of six CK2 phospho-acceptors 
within the C-terminal domain of I"B – a negative regulator of NF-"B (97).  This signal 
appears to emanate from p38-induced activation of CK2, as I"B phosphorylation is lost 
in when p38#-/- MEFs are stimulated with UV (97).  A role for p38 in stimulating CK2 
activity has also been observed in response to other cell stressors such as anisomycin, 
TNF# (tumour necrosis factor-alpha) and arsenite, and appears to occur via direct 
binding of active p38 to CK2 (98).  CK2 also participates in hierarchical phosphorylation 
which represents an emerging paradigm that can partly explain how a generally 
constitutively active kinase is controlled (99).  Given the tendency of CK2 to 
phosphorylate residues downstream of acidic amino acids, it is perhaps not surprising that 
phospho-residues also promote phosphorylation by CK2.  For example, following 
double-stranded DNA breaks, S14 phosphorylation of Rad51 by Plk1 generates a 
phospho-acceptor for CK2 at T13 (100).  Similarly, Src phosphorylation of C-Raf at 
Y340/Y341 promotes CK2 catalyzed phosphorylation at S338 (101).  In this way, 
hierarchical phosphorylation has the interesting characteristic of subjecting CK2 to the 
same regulatory control as the priming kinase (99).         
 
1.4 EVIDENCE FOR PATHOLOGICAL FUNCTIONS OF CK2 
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 CK2 has garnered interest as a candidate for targeted cancer therapeutics, 
especially of late, with the number of patents for CK2 inhibitors being filed dramatically 
increasing over the past 5 years (reviewed in (12)).  Largely, interest in CK2 as an 
inhibitor target is rooted in a body of literature that explores, via genetic and 
pharmacological means, the impact of manipulating CK2 activity on cell survival and 
proliferation (reviewed in (102)).  Below, we will highlight work that supports the 
establishment of CK2 as a candidate for targeted cancer therapeuty. 
 
1.4.1 CK2 over-expression in disease and model systems 
Evidence acquired as early as the 1980s indicated upwards of 3 to 8-fold greater 
CK2 activity in human breast and colorectal carcinoma samples compared to healthy 
tissue (103,104).  Since then, increased CK2 levels and/or activity have been observed in 
large variety of human cancers, including: breast (64,105), prostate (106), lung (107), 
head and neck (108), colorectal (109), gastric (110), leukemia (111), and kidney (112).  
Upon the development of transgenic mouse models that overexpress CK2!, a causative 
relationship between increased CK2 and the development of cancer was born.  
Transgenic CK2! overexpressed in T-cells or the breast showed an increase in 
lymphoma and mammary tumourigenesis, respectively (105,113).  Furthermore, 
oncogenic co-operativity was observed when mice with T-cell specific overexpression of 
CK2! were cross-bred with mice over-expressing the tal-1 or myc oncogene or those that 
were p53-/- (113-115).   
In cell culture, ectopic expression of CK2 appears to have only slight effects on 
proliferation.  Over-expression of CK2! or !" does not appear to overtly alter growth rate 
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in U2-OS (116), Chinese Hamster Ovary or 3T3 L1 cells (117), though cooperation 
between catalytic CK2 and Ras was observed when Balb/c 3T3 co-transfections exhibited 
significantly quicker growth compared to transfection of single genes (118).  Similarly, 
over-expression of CK2! in U937 leukemic cells had a slight, albeit significant reduction 
of cells in G0/G1, which reinforces the pro-survival role of CK2 (119). 
 
1.4.2 Neutralizing CK2 activity in disease models 
The functionality of high CK2 activity in cancer is most apparent when this 
activity is neutralized. Indeed, a positive correlation between CK2 levels and cellular 
sensitivity to various small-molecule CK2 inhibitors has been established.  Cell viability 
of T cell acute lymphoblastic leukemia was significantly decreased by TBB and DRB – 
two chemically unrelated CK2 inhibitors – whereas healthy thymus cells were not 
affected by these drugs (120) (Figure 1.3).  Similarly, Kim and colleagues (2007) found 
that primary samples of AML (acute myeloid leukemia) characterized by high CK2! had 
a significantly greater apoptotic response to apigenin, a moderately selective CK2 
inhibitor (45), compared to CK2-low AML and bone marrow mononuclear cells (119).  
Also, Donor patients of the CK2-high AML had significantly lower survival and disease-
free survival.  Furthermore, and perhaps not surprisingly, inhibition of CK2 signaling 
cooperates with a plethora of other apoptotic or chemotherapeutic agents to reduce cell 
viability, including nocodazole (121), gemcitabine (94), cisplatin (94), erlotinib (122), 
neocarzinostatin (123), thioguanine (124), IR (125), and TRAIL (tumour necrosis factor-
related  apoptosis-inducing ligand) (126,127).  CK2 inhibition is also effective against 
cell lines that have a selected resistance against chemotherapeutic agents such as  
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Figure 1.3 Selected examples of CK2 inhibitors.  Five commonly used CK2 inhibitors are 
depicted, including the current ‘gold standard’, CX-4945.  A complete review of CK2 
inhibitors is beyond the scope of this thesis and can be found elsewhere (234). 
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vinblastine or imatinib (128,129).  In these instances, resistant cell lines are actually more 
sensitive to CK2 inhibitors than cells sensitive to vinblastine or imatinib, consistent with 
the notion that CK2 activity plays a key role in supporting cell viability under stress.   
 
1.4.3 Perspectives: CK2 as a therapeutic target 
The protective role of CK2 in cancer cell survival suggests that these cells can 
become ‘addicted’ to CK2 activity (130).  Furthermore, CK2 appears to fit the 
classification of a non-oncogene (131). Conceptually, non-oncogenes encode a class of 
proteins that are not mutated in cancer, nor sufficient to transform cells in isolation, but 
nevertheless appear to be high-jacked and perform a specific function that for a given 
tumour type increases fitness – a concept termed ‘non-oncogene addiction’ (132).  In this 
regard, CK2 inhibition has the peculiar characteristic of generating different phenotypes 
depending on the genetic background.  Transient knockdown of CK2 causes apoptosis in 
MiaPaCa2 cells (133), numerous prostate cancer cell lines in culture and in mouse 
xenografts (134,135), and PANC-1 cells (136), but autophagy in glioblastoma cells (137).  
Similarly, treatment of BT-474 cell with CX-4945 (Figure 1.3), the most specific CK2 
inhibitor generated to date, causes a G2 arrest, but a G1 arrest in BxPC-3 cells (138).  
Nevertheless, targeting non-oncogenes using small-molecules has the added benefit that 
resistance mutations, either at the amino acid level or gross over-expression by gene 
duplication, are much less likely to occur over the course of treatment.  Indeed, chronic 
imatinib treatment for CML (chronic myelogenous leukemia) has led to resistance 
mutations in the oncogenic driver kinase Bcr-Abl (139,140) and similarly, B-raf 
inhibitors can lead to copy number gains in B-raf of some patients (141).   
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Taken together, it is clear that CK2 levels are increased in cancer and that 
targeting CK2 activity quells cancer cell survival and represents a powerful cancer 
targeting strategy.  It follows that CX-4945 has recently entered human clinical trials for 
the treatment of ovarian cancer and non-small cell lung carcinoma and is the first CK2 
inhibitor to do so.  Somewhat less satisfying are the unknown regulatory mechanisms 
controlling increased CK2 levels in cancer.  As mentioned earlier, there are no known 
mutations of CK2, either activating or inhibitory, that occur in disease suggesting that the 
high activity of CK2 in cancer results from altered levels of CK2 itself.  
Transcriptionally, all three CK2 genes have Ets response elements located upstream of 
the coding region (142,143).  However, that CK2 mRNA expression is ubiquitous 
throughout mouse tissue (144), while protein expression is not supports the existence of 
control mechanisms affecting translation and/or protein stability (34).  With respect to the 
latter, CK2 has a long half-life (24 h) (145) and the CK2! subunit is turned-over by 
ubiquitination (68), but how these processes are altered in cancer remains unknown.    
     
1.5 CK2 SUBSTRATES THAT MEDIATE THE PATHOLOGICAL PHENOTYPE 
The correlation between CK2 activity and cancer cell survivability indicates that 
the selective advantage mediated by CK2 is driven by the phosphorylation of CK2 
substrates – presumably the hyper-phosphorylation of physiological targets and possibly 
phosphorylation of pathological substrates.  As mentioned earlier, CK2 has a large 
repertoire of documented substrates implicated in cancer signaling pathways such as 
PI3K/Akt, NF-"B, Wnt, Hsp90, caspase cascades and DNA damage. Below we will 
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highlight a handful of bona fide substrates whose hyper-phosphorylation has a 
documented role in contributing to cell survival. 
The negative correlation between CK2 activity and PML (promyelocytic 
leukemia protein) levels represents one of the most clearly defined links in CK2 and 
disease.  PML is a scaffolding protein that coordinates nuclear bodies responsible for 
transmitting pro-apoptotic signals (146).  Importantly, PML protein levels are low in a 
number of cancer lines as a result of ubiquitin-mediated degradation that is signaled only 
after phosphorylation at S517 by CK2 (147).  Furthermore, Scaglioni and colleagues not 
only correlate PML levels to CK2 inhibition using small molecule inhibitors, but also 
show that S517A mutants resist degradation and are tumour suppressive in mouse models 
of lung cancer. Interestingly, PML phosphorylation by CK2 is also mediated by EBV 
infection (148).  Another CK2 substrate believed to be functionally relevant in cancer is 
cdc37.  As a kinase-specific chaperone, cdc37 acts in conjunction with Hsp90 to stabilize 
client kinases (149), most notably Raf-1 (150), but only when phosphorylated at S13 by 
CK2 as S13A mutants fail to bind kinase clients (151).  Kinase stabilization is 
particularly relevant to cancer treatment, as a number of oncogenic kinases require the 
Hsp90/cdc37 chaperone system for stabilization and, therefore, activity (149,152).  pS13 
is negatively regulated by protein phosphatase 5 (PP5) and so may be susceptible to 
hyper-phosphorylation by CK2 in cancer cells with high CK2 activity, though this has 
only been tested in models utilizing ectopic CK2 (153).  Here, expression of CK2!, 
CK2" or both increased pS13 in COS7 cells, providing evidence that high CK2 activity 
can disrupt the kinase/phosphatase balance of pCDC37 and may be relevant in cancer 
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(61).  Along these lines, CK2 inhibition appears to cause decreased levels of a number of 
CDC37 client kinases in multiple myeloma cells (154). 
A direct role for CK2 in regulating the apoptotic machinery has also been 
described and is an emerging theme in the pathological functionality of CK2 in cancer.  
CK2 phosphorylates ARC (apoptosis repressor with caspase recruitment domain) at T149 
which leads to ARC binding to and inactivation of caspase-8 (155).  Furthermore, ARC 
over-expression, but not the T149A mutant, completely blocks apoptosis caused by 
caspase-8 over-expression in HEK293 cells.  While ARC expression is constrained to the 
heart and skeletal muscle in human physiology (156), ARC is also prevalent in numerous 
human cancer cell lines (157), is a prognostic indicator of poor outcome for AML 
patients (158), and promotes chemoresistance in mouse models of breast cancer (159).  
Whether ARC function in cancer is dependent on pT149 has not been tested, but the 
inactivity of T149A against caspase-8 suggests CK2 is required for the disease-driving 
functions of ARC.  CK2 also phosphorylates Bid (160) – a pro-apoptotic protein that 
participates in mitochondrial permeabilization only after proteolysis by caspase-2 or -8 
(161).  Subsequent release of cytochrome c and smac/Diablo results in caspase-9 
activation and a blockade of the inhibitory effect of IAPs on caspase activity, respectively 
(162).  Interestingly, CK2 phosphorylates Bid proximally to the scissile bond cleaved by 
caspases and functions by blocking the proteolytic generation of tBid and, therefore, 
mitochondrial permeabilization (160).  Indeed, non-phosphorylatable mutants of Bid are 
more quickly cleaved in response to caspase-8 activation.  Moreover, that the temporal 
separation between caspase-8 activation and tBid generation can be destroyed by CK2 
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inhibitors suggests that Bid phosphorylation may act as a check to incoming apoptotic 
stimulus (163).         
 
1.6 CK2 AND CASPASES 
The observation of high CK2 activity in cancer cells, and the identification of CK2 
substrates that are intimately involved in regulating apoptosis are consistent with notion 
that CK2 functions as a blockade to apoptotic signaling in cancer, thereby increasing 
cellular fitness for those cancer cells.  Substrates such as Bid and ARC reinforce this link, 
but evidence for a direct regulation of caspase activity by CK2 is also emerging and will 
be highlighted below. 
 
1.6.1 Caspases: General 
 Caspases are a family of 14 proteases best known for their role in inflammation 
and apoptosis.  Their name is derived from a mnemonic of cysteine-dependent aspartate-
specifc protease and they function by catalyzing the proteolytic cleavage of scissile bonds 
C-terminal to an aspartic acid through use of a conserved, catalytic cysteine residue 
(164).  The apoptotic caspases are further classified into two sub-groups based on both 
sequence conservation and hierarchy within the caspase cascade  (165) (Figure 1.4).  
Initiator caspases differ from executioners because of a larger pro-domain on the N-
terminus that mediate protein-protein interactions required for extrinsic and intrinsic 
apoptotic initiation (Figure 1.4).  The extrinsic apoptotic program relies on ligand 
engagement to receptors that co-ordinate the formation of the DISC (death inducing 
signaling complex).  Here, the N-terminal DED (death effector domain) of caspase-8 and  
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Figure 1.4 – Schematic representation of the apoptotic caspases.  Effector caspases, with 
the larger prodomain containing protein binding domains, are shown on top, and the 
smaller effector caspases shown below.  Processing sites are indicated at domain 
junctions, relatedness indicated on the left, and length in amino acids on the right.  This 
figure is an adaptation from (235) and (236). 
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-10 are recruited to the DISC and achieve catalytic competency through proximity-
induced dimerization (166-168).  The intrinsic pathway is induced by ER stress or DNA 
damage (169).  Ultimately, pro and anti-apoptotic Bcl2 protein family members (which 
themselves are heavily regulated, but beyond the scope of this thesis) act as sentinels for 
apoptotic stimuli and transmit their signal by modulating mitochondrial membrane 
integrity (reviewed in (170)).  Breach of the mitochdondrial membrane releases 
cytochrome c which causes oligomerization of Apaf-1 and formation apoptosome (171), 
a so-called soluble receptor capable of binding the CARD (caspase activation and 
recruitment domain) containing pro-domain of caspase-9.  Like caspase-8, recruitment to 
the signaling complex mediates proximity-induced dimerization and activation of 
caspase-9 (172).  In contrast, the executioner caspases become activated only after 
cleavage by initiator caspases at conserved aspartic acid residues between the large and 
small subunit (Figure 1.4).  Cleavage does not alter greatly the overall structure of 
dimerized caspase-7, for instance, but permits maturation and exposure of the active site 
(173,174).  Once active, the executioners deliver the apoptotic message through 
proteolysis of key structural and enzymatic proteins (9).  Importantly, caspases generate a 
limited digestome; caspase substrates appear to have co-evolved and are not driven solely 
by the presence of an exposed aspartic acid and consensus motif determinants, but are 
affected by structural elements of the substrate as well (175).   
 Given the dire cellular consequences of caspase activation, it is not surprising that 
caspases are exquisitely regulated by a number of mechanisms.  As mentioned above, the 
intrinsic pathway controls caspase activation indirectly through the integrity of the 
mitochondrial membrane.  Mitochondrial permeabilization results in the release of the 
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aforementioned cytochrome c, but also Smac and Omi, which function by binding and 
inactivating inhibitors of apoptosis proteins (IAPs) (176,177).  IAPs are a family of 
proteins characterized by containing at least one baculoviral repeat domain which bind to 
and inactivate mature caspases -3, -7 or -9 (reviewed in (178)).  IAPs themselves are 
often over-expressed in cancer (179,180), and therefore Smac mimetics that bind to and 
inhibit IAPs are currently being pursued as a therapy for inducing apoptosis of various 
cancers (reviewed in (181)).   Another endogenous inhibitor of caspase activity is FLIP 
(FLICE-inhibitory protein) (182).  In this case, inhibition is mediated by blocking the 
maturation of caspase-8, as FLIP functions as a decoy molecule that prevents the 
formation caspase-8 dimers, and therefore the proximity induced dimerization and 
apoptotic activity of caspase-8 (183).  Interestingly, CK2 inhibition has been implicated 
in reducing FLIP expression, and sensitizing endometrial cancer cells to extrinsic 
apoptotic inducers (184).  Finally, phosphorylation of caspases by a variety of kinases is 
also implicated in both positively and negatively regulating caspase activity (reviewed in 
(5)).  Perhaps the most well studied example is the inhibitory phosphorylation of caspase-
9 at Thr125 by ERK (185), CDK1 (cyclin dependent kinase 1) (186), DYRK1A (dual 
specificity tyrosine-phosphorylation-regulated kinase 1A) and p38! (187).  
Phosphorylation of caspase-9 occurs under resting conditions (187), but also in response 
to activated MAPK signaling (185), mitosis (186) and osmotic stress (187) and reduces 
caspase-9 activation and apoptosis.  pT125 may also have clinical relevance in cancers 
such as gastric carcinoma, where tissue microarray staining suggested that 50% of 
samples tested stained positively for this post-translational modification (188).  Other 
examples include caspase-8 phosphorylation by Src family tyrosine kinases at Y380 
 28 
which inhibits activation in response to Fas ligand (189), and caspase-2 phosphorylation 
by CDK1 at S340 which safeguards against caspase-2 activation during mitosis (190).  
Taken together, apoptotic progression is regulated at the level of both initiator and 
executioner caspases by a number of diverse mechanisms.  
It should be noted that caspase activation and the execution of apoptosis are not 
mutually exclusive.  In one instance, caspase inhibition of apoptotic cells only forces 
mature B lymphocytes to undergo necrosis (191), a form of cell death characterized by 
organelle and cell swelling that leads to plasma membrane rupture (192).  As mentioned 
above, the activation of the intrinsic apoptotic pathway is controlled by mitochondrial 
integrity.  That caspase blockage is downstream of mitochondrial permeabilization led to 
the conclusion that caspase-independent cell death occurs largely through toxicity 
accompanied by disrupting mitochondrial function (193,194).  However, and pertinent to 
the survivability of cancer cells, caspase-independent cell death induced by mitochondrial 
disruption can be overcome by GAPDH (glyceraldehyde 3-phosphate dehydrogenase) 
(195).  Here, GAPDH serves a protective function by increasing ATP production and 
perhaps promoting the autophagic clearance of damaged mitochondria.   
On the flip side of cell death in the absence of caspase activity, limited caspase 
activation has a role in functions beyond apoptosis, such as differentiation and cell 
survival.   In the case of cell survival, caspase-8 activity is controlled by 
heterdimerization with the decoy molecule FLIP and found to alter the recognition motif 
when compared with homodimers (183).  These heterodimers result in cleavage of CYLD 
(196) and protection of cell death induced by RIPK1 (197).  Limited caspase-3 activity 
also directs differentiation of hematopoietic (198), embryonic (199), neural (200), 
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skeletal (201), bone marrow stromal (202).  Most pertinent for our discussion was the 
observation that caspase-cleaved connexin 45.6 only occurs in differentiated chick lens 
cells, but previous phosphorylation by CK2 at S363 is sufficient to block proteolysis 
connexin 45.6 (203).  Taken together, caspase activity performs diverse functions and is 
exquisitely regulated by a number of mechanisms.  
 
1.6.2 CK2 regulates caspase activity  
 The examples of ARC, Bid, and even PML, phosphorylation represents clear 
transmittance of an anti-apoptotic signal that emanate from CK2.  Via the 
phosphorylation of caspases themselves, CK2 is also able to control apoptosis by 
regulating caspase activity (Figure 1.5).  In one example, CK2 phosphorylates caspase-2 
in the pro-domain at S157 (204).  Phospho-caspase-2 is unable to dimerize and achieve 
catalytic competency, whereas S157A mutants auto-activate.  Furthermore, CK2! 
knockdown is sufficient to drive caspase-2 auto-activation, as is the CK2 inhibitor DRB.  
CK2 also phosphorylates murine caspase-9 proximally to the processing site between the 
large and small subunit (205).  Much like Bid, phosphorylation of caspase-9 is sufficient 
to block proteolysis catalyzed by caspase-8 and delay apoptosis cued by the DISC.  The 
phospho-acceptor responsible for cleavage blockade is not conserved in human caspase-
9, but nonetheless represents another intriguing example by which phosphorylation 
prevents caspase-mediated degradation.  Indeed, a number of other CK2 substrates are 
also controlled in this way (6) – a regulatory process we have named ‘phospho-blocking’ 
– and represents the over-arching theme of this thesis (Figure 1.5).  
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Figure 1.5 – Overview of kinase governance of caspase activity.  Caspase activity is 
controlled in a number of ways by kinases.  Most obviously, kinase phosphorylation of 
caspases can have a direct effect on the catalytic activity of caspases (reviewed in (5)).  
As well, indirect modulation of caspase activity can occur through phosphorylation of 
caspase substrates.  Here, phosphorylation near the scissile bond blocks proteolytic 
processing.  In this example, phosphorylation at P1! is depicted, but inhibitory 
phosphorylations at P2 and P4 have also been observed (215). 
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1.6.3 Regulation of caspases by phospho-blocking 
 By definition, caspases hydrolyze the peptide bond on the C-terminal side of the 
aspartic acid, or P1, residue.  This P1 residue is recognized by the caspase S1 binding 
pocket – an oxyanion hole that hydrogen bonds with remarkable specificity to the 
carboxyl moiety of aspartic acid (206) (4 orders of magnitude more specific for Asp than 
Glu (207)).  Similarly, substrate residues that reside roughly four amino acids upstream 
of P1, termed P2-P4, also make significant contacts with binding sites S2-S4 on the 
active caspase.  Structural alignments of caspase-1, -3, -7 and -8 reveal that substrate 
recognition is guided by the size and chemical nature of the binding pockets (208).  The 
P4-P1 determinants have also been rigorously characterized through positional scanning 
peptide libraries (207,209), and motif analysis of caspase substrate cleavage sites either 
curated from the literature (210) or generated from proteomic datasets (211-214).  
Amongst the trends emerging from a superficial analysis of caspase consensus motifs is 
the presence of acidic determinants for at least two of the four positions within the 
recognition sequence (207,209).  In spite of this, but consistent with the observation that 
phosphorylation of Bid and caspase-9 blocks proteolysis by upstream caspases, phospho-
residues located at P4, P2 and P1! reduces proteolysis of peptide substrates catalyzed by 
caspase-3 and -7 and phospho-P2 impairs cleavage by caspase-8 (215).  Furthermore, and 
as alluded to earlier, phospho-blocking also regulates a number of protein substrates 
(Table 1.1), and in some instances, alters apoptotic progression.     
Prominent examples of phospho-blocking affecting apoptotic progression include 
the aforementioned Bid.  The location of Bid within the apoptotic cascade makes its 
cleavage and activation a powerful control point; only after processing by caspase-8 does  
 32 
 
 
 
 
Protein Site Kinase Block Promote Alter Apoptosis Reference 
Bid  T58, 
S61 
CK2, 
CK1 
X  X (160) 
Caspase-9 
(mouse) 
S348 CK2 X  X (205) 
PTEN S370, 
S385 
CK2 X   (218) 
Max S11 CK2 X   (219) 
Connexin 
45.6 
S363 CK2 X   (203) 
HS1  CK2 X   (220) 
YY1 S118 CK2 X   (221) 
Presenilin-2 S327, 
S330 
CK2, 
CK1 
X  X (216,222) 
Presenilin-1 S346 PKC   X (223) 
Acinus* S422, 
S573 
Akt X  X (224) 
Caspase-2 S340 Cdk1 X†  X (225) 
Caspase-8 S387 Cdk1 X†  X (226) 
Caspase-8 S380 Src X†  X (189) 
MST1* S387 Akt X  X (227) 
MST1 S327 MST1 X   (228) 
PLC-!1 Y771 EGFR X   (229) 
I"B-# 
(chicken) 
S35 I"B-# 
kinase 
X   (230) 
Nogo-B S16 Cdk1 X   (231) 
PKC$ Y332 Src  X X (232) 
 
Table 1.1 – Previously demonstrated examples of phosphorylation-dependent regulation 
of caspase-mediated cleavage 
 
*phosphorylation distant (>10 amino acids) from scissile bond 
†Direct evidence does not exist for blockage, but phosphorylation sites are located in the 
interdomain linker region, and apoptosis is reduced. 
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it promote mitochondrial permeabilization and effector caspase activation.  Interestingly, 
targets downstream of executioner caspases can also impair apoptotic progression.  
Phospho-mimetic mutants of Presenilin-2 block its own cleavage by caspase-3, but also 
the cleavage of PARP, another executioner caspase substrate (216).  DNA fragmentation, 
another metric for apoptotic progression is also delayed in this instance.  Collectively, 
these examples, and others from Table 1.1, highlight phospho-blocking as an important 
regulator of apoptotic progression.  
 
1.7 RATIONALE FOR STUDY 
 Much like caspases, the CK2 consensus motif consists predominately of acidic 
residues, especially at the n+1 and +3 positions, and more generally at positions 
anywhere from -2 to +7 (20-23).  Given the shared features of the caspase and CK2 
recognition motifs, and the constitutive activity of CK2, it may come as little surprise that 
a number of caspase substrates are phosphorylated by CK2 near the scissile bond and 
alters caspase cleavage (Table 1.1).  Furthermore, the hyperactivity of CK2 in cancer and 
the general anti-apoptotic role of this activity implies that phospho-blocking of caspase 
substrates by CK2 may globally regulate the caspase degradome on a larger scale than 
previously appreciated (6,217).  This presumption is also supported by the observation 
that caspase inhibition during cell stress can rescue cell death, and that phospho-blocking 
of other caspase substrates reduces apoptotic progression. 
Another important consideration when studying CK2 relates to its enigmatic 
regulation.  It is constitutively active, yet is controlled in cells through subtle mechanisms 
(73).  Perhaps the most perplexing regulatory feature governing CK2 activity is the  
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regulatory subunit itself – CK2!.  CK2! controls substrate specificity of a few substrates, 
but is thought to not affect phosphorylation of the majority of targets (52).  As well, the 
holoenzyme forms readily in vitro and will dissociate only under denaturing conditions 
(36).  However, there is indirect evidence for free-catalytic specific functionality in cells, 
yet these studies are often anecdotal and provide indirect evidence.  Therefore, 
biomarkers that can unambiguously probe for the presence of different forms of CK2 in 
cells will bolster the understanding of CK2 regulation and how it contributes to disease 
processes such as apoptosis.  
 More generally, the emergence of an integrated network of phosphorylation and 
caspase-mediated proteolysis suggests apoptotic regulation extends beyond just CK2 
(5,6).  Indeed, a number of phospho-blocked substrates are phosphorylated by other 
kinases also implicated in oncogenesis (Table 1.1).  However, a remaining challenge in 
studying this signaling mechanism is its complexity; the dynamic nature of 
phosphorylation networks in cells make identifying hierarchically regulated cleavage 
events difficult when studying entire proteomes.  Indeed, the only phospho-blocked 
caspase substrates identified to date have been found serendipitously.  Moving forward, 
unbiased strategies that aim to identify novel phospho-blocking events will be crucial in 
defining this important signaling mechanism.      
 
1.8 SCOPE OF THESIS 
 Given the documented integration of CK2 within the apoptotic and caspase 
signaling networks, we first set out to identify CK2 phosphorylation events that function 
to block caspase-mediated degradation.  In chapter 2, we utilized peptide-match programs 
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that aligned putative CK2 phospho-acceptors directly proximal to predicted caspase 
scissile bonds.  Interestingly, we uncovered and validated that CK2 phosphorylation of 
caspase-3 itself prevents its activating cleavage by initiator caspases -8 and -9 using 
recombinant proteins.  Furthermore, we found that caspase-3 is phosphorylated 
exclusively by free-catalytic CK2, prompting development of phospho-specific 
antibodies to study caspase-3 phosphorylation in cells.  These antibodies represent the 
first biomarker for a free-catalytic specific substrate of CK2.   
 In chapter 3, we utilized our phospho-specific caspase-3 antibodies to study 
phosphorylation of a free-catalytic specific substrate in cells.  Interestingly, ectopic 
expression of only CK2!", but not CK2!, resulted in phosphorylation of caspase-3, 
highlighting divergent functions for these extremely similar kinases.  We also provide 
evidence that isozyme preference is not the result of differences in binding to 
endogenous, cellular CK2#, supporting a role for other regulatory factors in controlling 
substrate access.  Given the unbalanced expression of CK2 subunits in disease tissues 
from cancer patients, our work provides evidence that the CK2 phospho-proteome may 
depend on the complement of CK2 subunits present.  Furthermore, in cancer cell lines or 
tissues where CK2!" is high and CK2# is low, phosphorylation of caspase-3 may 
represent a mechanism by which CK2 promotes anti-apoptotic signaling. 
 Finally, in chapter 4, we sought to develop unbiased methods to identify 
phosphorylation events that alter cleavage by caspases.  To this end, we utilized a 
proteomic strategy that enriches proteomes for neo-N-termini generated by lysate 
protease treatment.  In our case, HeLa lysates were treated with or without $ phosphatase, 
followed by caspase reactions.  We validated three substrates as having altered cleavage 
 36 
kinetics as a result of lysate dephosphorylation; Golgin-160 and Yap1 were phospho-
blocked, whereas MST3 was actually cleaved less after dephosphorylation.  We 
supplemented this work with a systematic investigation of the determinant properties of 
phosphorylated-Ser when positioned throughout the entirety of an extended caspase motif 
on model substrate peptides.  Phosphorylation was generally inhibitory towards 
proteolysis, even at residues beyond the canonical caspase motif.  Collectively, this work 
suggests that phosphorylation events that positively regulate cleavage do so by 
mechanisms controlling scissile bond accessibility.  Furthermore, we demonstrate the 
utility of unbiased approaches to identify novel cleavage events regulated by 
phosphorylation. 
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CHAPTER 2 – PREDICTION AND CHARACTERIZATION OF CASPASE-3 AS 
A SUBSTRATE OF PROTEIN KINASE CK2 
 
2.1 INTRODUCTION 
Protein kinase CK2 is a highly conserved, constitutively active Ser/Thr kinase that 
is overexpressed in a number of human cancers (1,2).  Illustrating its emergence as a 
cancer therapeutic target, inhibition of CK2 by genetic or pharmacological means is 
detrimental to cancer, but not healthy cell proliferation and survival (3-5).  As a result of 
its constitutive activity and high abundance in cells, CK2 phosphorylates a large number 
of substrates – on the order of thousands, according to some estimates (6) – and, not 
surprisingly, participates in a number of cellular processes including anti-apoptotic 
signaling (2,7).  Given the ability of cancer cells to evade apoptosis and perpetuate 
inappropriate cell growth, current dogma holds that the role of CK2 in cancer pathology 
is likely carried out by the inappropriate or hyperphosphorylation of apoptotic signaling 
proteins, which then act to sustain an anti-apoptotic stimulus.  Identifying 
hyperphosphorylated CK2 substrates that perpetuate pro-survival signaling will be crucial 
in delineating how best to exploit CK2 inhibitors for targeted therapeutics. 
Apoptotic stimuli ultimately impinge upon and activate caspases – a family of 
cysteine-dependent, aspartate-specific proteases that execute cell death by cleaving key 
structural and enzymatic proteins (8).  Perhaps not surprisingly, caspases are regulated by 
kinases at multiple levels (9).  Phosphorylation of proteins controlling apoptotic 
initiation, such as the Bcl2 family members Bid (10) and Bad (11), for example, and 
caspases themselves are well documented to alter caspase activity.  Interestingly, caspase 
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activity is also controlled indirectly via the phosphorylation of their substrates, a number 
of which are targets of CK2.  Here, phospho-residues in close proximity to the scissile 
bond, most notably at P2 or P1!, hamper substrate cleavage (12).  Furthermore, not only 
does phosphorylation of Bid (10) and Presinilin-2 (13) by CK2 reduce their susceptibility 
to caspase cleavage, but it also dulls the apoptotic response. 
The identification of a number of CK2/caspase substrates has led us and others to 
hypothesize that CK2 may phosphorylate a number of other caspase substrates (1,14).  In 
large part, this postulation is strengthened by the observed consensus motifs for CK2 and 
caspases.  By definition, caspases cleave the scissile bond at a P1 Asp, but also prefer 
Asp or Glu at P3 and P4, for executioner caspases-3, and -7, and Glu at P3 for initiator 
caspase-8 and -9 (15).  Similarly, CK2 phosphorylates substrates preferentially at Ser/Thr 
residues that are upstream of acidic amino acid determinants.  Asp or Glu residues at n+3 
and, to a slightly lesser extent, n+1 are the strongest determinants, but phosphorylation is 
generally increased by acidic amino acids from n-2 to +7 (16-19).  Taken together, the 
constitutive activity of CK2 and the general similarity between the caspase and CK2 
consensus motifs may explain the relatively large number of previously identified 
CK2/caspase substrates whose phosphorylation blocks caspase cleavage (12).  
Furthermore, the anti-apoptotic role of CK2 upon over-expression highlights the 
possibility that the convergence between CK2 and caspase signaling represents a global, 
previously underappreciated mechanism by which CK2 promotes cell survival.   
In an effort to identify CK2 substrates that are phosphorylated proximally to a 
caspase cleavage site, we interrogated the proteome for sequences containing an 
overlapping CK2/caspase motif.  To the best of our knowledge, this is the first predictive 
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analysis investigating the hierarchical regulation of kinases and caspases.  Comparative 
analysis between our predictions and phospho-proteomic or caspase databases identified 
a number of candidates that contained one of the predicted post-translational 
modifications.  Significantly, we found that caspase-3 itself contains a putative CK2 
phosphorylation site directly adjacent to the scissile bond whose cleavage by upstream 
caspases is required for activation.  We validated that recombinant caspase-3 is 
phosphorylated by CK2 at the predicted sites and that phosphorylation does indeed block 
proteolysis by caspase-8 and-9.  In characterizing caspase-3 phosphorylation, we found 
that it is actually blocked by the regulatory CK2! subunit, a rare characteristic of CK2 
substrates that may have implications for the physiological regulation of caspase-3 by 
CK2.  Finally, we developed phospho-specific antibodies of caspase-3, which lay the 
groundwork for testing the pathological significance of caspase-3 phosphorylation in 
cells expressing high levels of CK2.   
       
2.2 MATERIALS AND METHODS 
 
2.2.1 Bioinformatics and database searching 
We designed a Perl based peptide match program to search the human proteome 
databases (Swiss-Prot and National Center for Biotechnology Information, 07/10/12) for 
overlapping CK2 and caspase consensus sequences.  Overlapping motifs were designed 
such that the putative phospho-acceptor (S/T-X-X-D) is positioned at P2 or P1" of the 
predicted scissile bond for caspase-3/-7 (D-E-X-D) and caspase-8/-9 (I/V/L-E-X-D).  
After a proteome-wide search for matching peptides was performed, the peptide match 
software returned the GI number, Swiss-Prot primary accession number, and the Swiss-
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Prot protein ID, as well as the sequence of the matching peptide (±10 amino acid residues 
on either side of the recognized peptide pattern).  Subsequently, database mining was 
performed by manually searching a caspase substrate database (CASBAH) (20), and 
phosphorylation databases (Phosida and UniProt KB) (21) for the predicted CK2/caspase 
modifications. 
 
2.2.2 Generation and purification of caspase-3 and related mutants 
Catalytically inactive His-tagged caspase-3 (ATCC) was engineered using a 
QuickChange II Site-Directed Mutagenesis Kit (Stratagene).  Human caspase-3 pET23b 
was PCR amplified to make the (C163A) mutation to abolish catalytic activity thereby 
allowing for purification of full-length caspase-3 using the primer 5’-
TTCATTATTCAGGCCGCCCGTGGTACAGAA-3’.  In all cases, recombinant caspase-3 used in 
this study contains C163A mutation and, therefore, is the full-length, zymogen form.  
Phosphorylation mutants (T174A), (S176A) and (T174A S176A) of caspase-3 were 
generated using the following primers 5’-GACTGTGGCATTGAGGCAGACAGTGGTGGTGAT-
3’, 5’-GGCATTGAGACAGACGCTGGTGGTGATGAC-3’, 5’-
GACTGTGGCATTGAGGCAGACGCTGGTGTTGATGATGAC-3’, respectively. caspase-3 
(C163A) and the phosphorylation mutants were purified with a HiTrap SP HP column 
(Amersham Biosciences) using the AKTA Purifier FPLC (Amersham Biosciences).  
Purified, recombinant caspase was then dialyzed into 50% glycerol, 50 mM Tris 
(tris(hydroxymethyl)aminomethane) (pH 7.5), and 150 mM NaCl and stored at -20°C. 
 
2.2.3 In vitro phosphorylation of caspase-3 by GST-CK2!  
 64 
In vitro kinase assays were performed using recombinant, 6!His-tagged, full-
length, inactive (C163A) caspase-3.  For phosphorylation, 0.5 – 2 µg of recombinant 
caspase was incubated with 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.1 
mM ATP, 0.2 µCi ["-32P]-ATP and 35 ng of recombinant GST-CK2# for 20 min at 30°C.  
Assays investigating stoichiometry of phosphorylation or being used for downstream 2D-
peptide mapping were allowed to run for 2 h.  Reactions were stopped by the addition of 
SDS sample buffer and proteins resolved by 10% SDS-PAGE gel electrophoresis.  Gels 
were then dried and radiolabeled proteins visualized using a phosphorimager. The 
relative amount of 32P incorporation was determined using ImageQuant TL software.   
For kinetic analysis of caspase-3, calmodulin and #-casein, 0.5 – 8 µM purified 
protein substrate was reacted with CK2 and terminated by adding 2! SDS sample buffer.  
Reactions were performed for 5 and 10 minutes to verify linearity.  The holoenzyme was 
reconstituted by incubating equimolar amounts of His-CK2$ and GST-CK2# for 5 
minutes prior to the assay.  Samples were processed by SDS-PAGE, stained with 
coommassie blue and then dried.  Phosphorylation was detected using a phosphorimager 
and absolute 32P incorporation was determined using ImageQuant TL software.  Kinetic 
constants were determined using GraphPad Prism software version 4.0. 
 
2.2.4 2D phospho-peptide mapping and phospho-amino acid analysis 
 2D phospho-peptide mapping was performed as previously described (22).  
Briefly, reactions were resolved by SDS-PAGE, the gel dried and bands corresponding to 
caspase 3 were excised.  Proteins were digested by trypsin overnight and then separated 
on thin-layer chromatography plates at 1000V (horizontal dimension) and by 
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chromatography in Scheidtmann buffer (vertical dimension).  Plates were analyzed by a 
phosphorimager.  Next, the indicated spots were scraped off the plate and processed for 
phospho-amino acid analysis.  Briefly, recovered peptides were partially hydrolyzed in 
constant boiling HCl as previously described (23).  Next, two-dimensional separation of 
partially hydrolyzed products was carried out as previously described (24).  Briefly, 
phospho-amino acids were spotted on thin layer chromatography plates and separated in 
pH 1.9 buffer (2.5% formic acid/7.8% glacial acetic acid) in the first dimension 
(horizontal in figures) and pH 3.5 buffer (0.5% pyridine/5.0% glacial acetic acid) in the 
second.  32P-amino acids were visualized using a phosphorimager and the presence or 
absence of phospho-amino acids was determined empirically. 
 
2.2.5 Cleavage of caspase-3 by caspase-8 and -9 
 To test the effect of caspase-3 phosphorylation on caspase-mediated cleavage, 2 
µg of purified caspase-3 were incubated with GST-CK2! in a kinase assay for 2 h as 
described above.  Following the kinase assay, 6 U/µl of caspase-8 (BIOMOL) or caspase-
9 (BIOMOL) was added to the kinase reaction in caspase assay buffer (50 mM HEPES, 
pH 7.4, 100 mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10% glycerol and 10 mM DTT) for 
caspase-8 or (100 mM MES, pH 6.5, 10% PEG (Polyethylene Glycol, average MW 
8000), 0.1% CHAPS, 10 mM DTT) for caspase-9 reactions.  Cleavage reactions were 
incubated overnight at 30 0C with gentle agitation to obtain optimal cleavage and then 
stopped by addition of SDS sample buffer.    Radiolabeled proteins were resolved on 12% 
SDS-PAGE electrophoresis, and gels were dried and visualized on a phosphorimager. 
Determination of the amount of 32P incorporated was assessed using ImageQuant TL 
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software. Non-radiolabeled cleavage reactions were performed in parallel to verify 
caspase-8 and -9 activity.  Cold kinase assays (non-radiolabelled ATP) were performed 
as above except were resolved on 12% SDS-PAGE, transferred to PVDF and probed with 
anti-caspase-3 antibodies.  
 
2.2.6 Western blotting  
Samples were separated by SDS-PAGE and transferred to PVDF using standard 
procedures.  Antibodies against caspase-3 (Cell Signaling Technology) and Phospho-
threonine (Cell Signaling Technology) were used.  Phospho-specific caspase-3 antibodies 
were generated against GIEpTDpSGVDDMAC by YenZym Antibodies, LLC, San 
Francisco, Ca using proprietary methods.  Secondary antibodies used were GAR-680 (LI-
COR Biosciences).  Densitometric analysis was performed using Odyssey software 
(version 3.0) from LI-COR Biosciences. 
 
2.3 RESULTS    
2.3.1 Identification of proteins with overlapping CK2 and caspase consensus motifs 
To test the hypothesis that CK2 phosphorylation sites frequently overlap caspase 
cleavage motifs, we undertook a bioinformatics approach that employed a novel peptide 
match strategy (Figure 2.1).  Using perl script, we developed a program to interrogate the 
human proteome for proteins containing overlapping CK2 and caspase consensus motifs 
that positioned the CK2 phospho-acceptor directly proximal to the scissile bond at P2 and 
P1!, sites previously shown to block cleavage of caspase substrate at both the protein and 
peptide level (12,25,26).  To determine which of the putative CK2/caspase substrates had  
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Figure 2.1 – Workflow for the identification of caspase substrates whose cleavage is 
regulated by CK2 phosphorylation.  Phospho-acceptors from a minimal CK2 consensus 
motif (blue) are positioned at P2 or P1! within a caspase consensus motif (red) and the 
proteome searched for these sequences using perl script.  Hits were cross analyzed using 
Phosida and UniProt KB to determine if putative phospho-acceptors were previously 
identified as phosphorylated in cells, and CASBAH to assess if there was precedent for 
the predicted scissile bonds to actually be cleaved by caspases. 
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Table 2.1A.  Amino acid sequences of putative CK2 and caspase-3/-7 substrates that have 
been previously identified to be phosphorylated in cells.  The identified motifs are 
highlighted in capitals.  Phosphorylation sites were identified by cross-referencing 
Phosida (21) and Expasy. 
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Table 2.1B.  Amino acid sequences of putative CK2 and caspase-8/-9 substrates that have 
been previously identified to be phosphorylated in cells.  The identified motifs are 
highlighted in capitals.  Phosphorylation sites were identified by cross-referencing 
Phosida (21) and Expasy. 
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Table 2.2.  Amino acid sequences of putative CK2 and caspase substrates that have been 
previously identified to be cleaved by caspases.  The identified motifs are highlighted in 
capitals.  Caspase cleavage sites were identified by cross-referencing CASBAH (20). 
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the predicted post-translational modification, we cross-referenced our bioinformatics data 
set against existing databases for phosphorylation (Phosida and UniProtKB) and caspase 
cleavage (CASBAH) (20,21).  59 of the 335 (17.6%) putative CK2/caspase substrates 
have previously been reported as phosphorylated in cells (Table 2.1A and 2.1B) 
illustrating the validity of the predictive approaches.  Furthermore, our peptide match 
strategy also identified 5 previously known caspase substrates (Table 2.2).  In 
establishing the highest priority candidates for testing if phosphorylation blocks cleavage, 
we gave precedence to proteins that: i) were previously identified as having at least one 
of the predicted post-translational modifications, and ii) has a pro-apoptotic function in 
cells upon caspase-catalyzed proteolysis.  Application of both of these criteria identified 
caspase-3 and -8 as candidate caspase substrates regulated by CK2 phosphorylation. 
Caspase-3 is an executioner caspase that is cleaved and activated by initiator 
caspases upon extrinsic or intrinsic apoptotic stimuli, and is responsible for the majority 
of caspase activity after engagement of the mitochondrial apoptotic pathway (27,28).  
Importantly, the phosphorylation site predicted by our screen reside at P1! within the 
cleavage site responsible for caspase-3 activation (29), and therefore, could act to block 
proteolysis by upstream caspases, and hinder apoptotic execution  (Figure 2.2A).  
Interestingly, this CK2 consensus motif (S/T-X-X-D/E) is conserved from humans to 
frogs, but is not present in caspase-6 or -7 – the other executioner caspases – implying 
specialized and conserved regulation for caspase-3 (Figure 2.2B).  The effect of caspase-
8 phosphorylation on activation was previously studied, and so will not be further 
discussed here (G. Poggenpoel, personal communication).    
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Figure 2.2 – Mechanism of caspase-3 activation. (A) The CK2 consensus site identified is 
located at the junction between the large and small subunit of caspase-3, where cleavage 
by caspase-8 or -9 is required to activate caspase-3.  (B) An alignment of the scissile 
bond between the large and small subunit of human executioner caspases and frog and 
mouse caspase-3 is presented.   
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2.3.2 CK2 phosphorylates caspase-3 at T174 and S176 in vitro 
 As a prelude to assessing the regulatory effects of caspase-3 phosphorylation on 
its cleavage, we first tested the hypothesis that caspase-3 is a substrate for CK2.  When 
reactions with GST-CK2! and caspase-3 were performed for 2 h, stoichiometry of 
phosphorylation approached 1.5 pmol of phosphate per pmol of caspase-3, indicating the 
presence of multiple phospho-acceptors (Figure 2.3A).  Next, we tested if CK2 
phosphorylated caspase-3 at the predicted CK2 phospho-acceptor, S176.  S176A caspase-
3 mutants resulted in decreased, but not abolishment of, phospho-incorporation (Figure 
2.3B).  Interestingly, T174 also conforms to a minimal consensus motif – albeit not the 
motif used in our bioinformatics analysis – as n + 1 acidic residues (16-19) are also 
positive determinants for CK2 phosphorylation.  Indeed, T174A mutants exhibited 
reduced phosphorylation compared to wild-type, and S176A/T174A double mutants were 
not phosphorylated (Figure 2.3B).  Phosphorylation of T174 was also tested using a 
generic P-Thr antibody.  Antibody reactivity was lost upon mutation of T174, but not 
S176, to alanine (Figure 2.3C).  Therefore, we successfully predicted S176 and 
serendipitously identified T174 as prominent CK2 phosphorylation sites on caspase-3.  
Like the Ser at P1", T174 at P2 is unique amongst the most closely related executioner 
caspases -6 and -7 and is conserved from Homo sapiens to Xenopus laevis (Figure 2.2B), 
suggesting the presence of specialized regulatory mechanisms.  
 In an effort to further evaluate the presence of pT174 and pS176, we performed 2-
dimensional, thin layer chromatography on tryptic peptides of phosphorylated mutant and 
wild-type caspase-3.  As seen in Figure 2.4A, mapping patterns of the single mutants are 
identical and do not yield new spots when samples are mixed and run together (data not  
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Figure 2.3 – Caspase-3 is phosphorylated by GST-CK2! at T174 and S176.  (A) 
Different amounts of recombinant caspase-3 were phosphorylated by GST-CK2! for 2 
hours and separated by SDS-PAGE.  The gel was dried and stoichiometry of 
phosphorylation was calculated after exposure to a phosphorimager.  (B) The indicated 
recombinant caspase-3 was phosphorylated by GST-CK2! and processed as above or (C) 
western blotted using anti-P-Thr or anti-caspase-3 antibodies as indicated. 
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shown).  In contrast, phospho-peptide maps of wild-type caspase-3 reveal two more 
prominent spots (labeled A and C in Figure 2.4A). Given the characteristic upward streak 
in the liquid chromatography phase of spot ‘A’ and ‘B’, and that ‘A’ and ‘C’ are 
equidistant from eachother as are ‘B’ and ‘D’, we reasoned that ‘A’ is the same peptide 
as ‘B’ – only doubly, rather than singly, phosphorylated.  Likewise, we hypothesized that 
‘C’ is the doubly phosphorylated counterpart of ‘D’.   
To test if spot ‘B’ contained singly phosphorylated peptides, we retrieved 
phospho-peptides from the mapping plates of mutant caspase-3 and performed phospho-
amino acid analysis.  Spot ‘B’ contained almost exclusively pSer and pThr for T174A 
and S176A mutants, respectively (Figure 2.4B), suggesting that this spot indeed contains 
singly phosphorylated peptide.  Similar results were also observed for spot ‘D’ of both 
mutants (data not shown).  Interestingly, phospho-amino acid analysis of singly 
phosphorylated spot ‘B’ from wild-type caspase-3 mapping plates revealed the presence 
of an approximately equal amount of pSer and pThr.  The presence of both phospho-
acceptors in a spot that co-migrates with peptides from single phosphorylation site 
mutants suggests that phosphorylation does not occur in a sequentially ordered fashion.  
Not surprisingly, spots ‘A’ and ‘C’, the predicted doubly phosphorylated peptides, also 
contained both pThr and pSer.     
 
2.3.3 CK2!  inhibits phosphorylation of caspase-3 by GST-CK2"  
 In an effort to fully characterize the phosphorylation of caspase-3 by CK2 in vitro, 
we performed kinase assays in the presence or absence of the regulatory CK2! subunit.  
Generally, CK2! stimulates the catalytic subunits of CK2 by 3-5 fold on most substrates  
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Figure 2.4 – 2D-peptide mapping and phospho-amino acid analysis reveals non-ordered 
phosphorylation of T174 and S176.  (A) Recombinant caspase-3 was phosphorylated by 
GST-CK2! for 2 h, digested with trypsin and separated by electrophoresis (horizontal) 
and chromatography (vertical).  Thin layer chromatography plates were imaged by 
autoradiography.  On the right is a schematic representation of the spot patterns generated 
by the wild-type and single mutant phospho-caspase-3.  (B) Spot ‘B’ from T174A and 
S176A plates were scraped off, partially hydrolyzed by boiling in acid and phospho-
amino acids separated by 2D-electrophoresis as described in the materials and methods.  
Plates were imaged using a phosphorimager. (C) Phospho-amino acid analysis of spots 
‘A’ – ‘D’ of wild-type phospho-caspase-3 was carried out as described in (B).    
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(30), but we found that CK2! almost completely abolished phosphorylation of caspase-3 
(Figure 2.5A).  Interestingly, when comparing GST-CK2" to commercially available 
holoenzyme or GST-CK2" supplemented with stoichiometric amounts of recombinant 
His-CK2!, we observed a decrease in the ratio of phospho- caspase-3 to phospho-casein.  
A detailed kinetic analysis using reconstituted CK2 holoenzyme confirmed these results 
and revealed that caspase-3 phosphorylation behaved similarly to calmodulin – a CK2 
substrate that was previously shown to be specific only for the catalytic subunit (Figure 
2.5B) (30).  In both cases, addition of the ! subunit reduced the kcat/Km (sec-1µM-1) by a 
factor of 20, while casein expectedly showed more favourable phosphorylation, further 
validating holoenzyme reconstitution after ! addition.  Also like calmodulin, poly-L-
lysine treatment of the holoenzyme rescues the inhibitory effect of CK2! on caspase-3 
phosphorylation (Figure 2.5C) (30,31).    
 
2.3.4 Phosphorylation of caspase-3 by GST-CK2 inhibits cleavage by initiator 
caspases 8 and 9 
 Following the identification of CK2 phosphorylation sites that flank the scissile 
bond on caspase-3, we next tested if phosphorylation blocks caspase-3 cleavage by 
upstream initiator caspases.  As judged by figure 2.6A and B, pre-phosphorylation of 
caspase-3 by CK2 significantly reduces the appearance of cleaved caspase-3 (17 kDa 
fragment) after incubation with initiator caspases-8 and -9.  Furthermore, we ran an 
experiment in parallel in which pre-phosphorylation of caspase-3 was performed with 
radiolabelled ATP-!-P32 (Figure 2.6A).  Here, the absence of a radiolabelled 17-kDa 
caspase-3 fragment after initiator caspase treatment further reinforces the notion that  
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Figure 2.5 – Phosphorylation of caspase-3 is inhibited by the regulatory CK2! subunit.  
(A) Three different preparations of CK2 were used to phosphorylate recombinant 
caspase-3 for 20 minutes.  In the case of the reconstituted holoenzyme, equimolar His-
CK2! was added to GST-CK2" and incubated for 5 minutes prior to starting the reaction 
to allow the holoenzyme to form. Reactions were separated by SDS-PAGE, the gels dried 
and visualized by a phosphorimager.  (B) Kinetic analysis of different CK2 substrates 
was performed with GST-CK2" or GST-CK2"/His-CK2! (hCK2).  Reconstitution of the 
holoenzyme and reaction visualization was performed as in (A) and the standard error 
from the mean calculated from three kinase reactions.  CAS = "-casein, C3 = caspase-3 
and CaM = calmodulin.  (C) Kinase assays were performed as in (A).  Poly-L-Lysine 
(PLL) was added to the holoenzyme 5 minutes prior to starting the kinase reaction. 
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Figure 2.6 – Phosphorylation of caspase-3 by GST-CK2! blocks proteolytic processing 
by caspase-8 and -9.  (A) Kinase assays with GST-CK2! and caspase-3 were performed 
for 2 h, followed by addition of active caspase-8 or -9 for an additional hour.  Reactions 
were performed with both ("-32P) ATP, to visualize phospho-caspase-3 (top panel), and 
‘cold’ ATP to visualize total caspase-3 (bottom panel).  (B) Cold kinase assays were 
performed as in (A) in triplicate and the percent cleavage, as determined by denistometric 
analysis of the cleaved caspase-3 fragment, plotted.  Error bars represent the standard 
error from the mean.  (C) Cold kinase assays were performed as in (A) using either wild-
type caspase-3 or the double phospho-acceptor mutant and TBB as indicated.    
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caspase-3 phosphorylated by GST-CK2 is resistant to proteolysis.  To test if binding of 
GST-CK2 to caspase-3, as opposed to phosphorylation, is responsible for the proteolytic 
blockage, we compared the cleavage of caspase-3 to a double phospho-acceptor mutant 
after pre-incubation with GST-CK2 and ATP.  That more cleavage appears with the 
T174A/S176A mutant is consistent with the hypothesis that phosphorylation, rather than 
binding by GST-CK2!, is responsible for inhibiting proteolysis of caspase-3 (Figure 
2.6C).  Furthermore, protection from cleavage can be rescued by co-treating pre-
phosphorylating assays with the CK2 ATP competitive inhibitor, TBB.     
 
2.3.5 Characterization of phospho-specific antibodies targeted against pT174/pS176 
of caspase-3 
 As a prelude to studying caspase-3 phosphorylation in cells, we undertook the 
development of affinity purified pT174/pS176 caspase-3 antibodies through a contract 
supplier.  To validate antibody specificity and sensitivity, we probed various forms of 
caspase-3, including wild-type, both single mutants and the double mutant after treatment 
with GST-CK2! (Figure 2.7).  Densitometric analysis revealed a time dependent increase 
in phospho-caspase-3 signal that mirrored that of 32P incorporation into caspase-3.  At a 
1:500 dilution, the anti-phospho-caspase-3 was able to detect approximately picomolar 
levels of phosphorylated caspase-3.  Furthermore, these antibodies were capable of 
detecting both phosphorylated T174A and S176A, but not the non-phosphorylatable 
mutant, validating antibody specificity. 
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Figure 2.7 – Characterization of pT174/pS176 phospho-specific caspase-3 antibodies. 
Recombinant caspase-3 and the corresponding single and double phosphorylation site 
mutants were phosphorylated by recombinant GST-CK2! with "-32P-ATP.  Samples 
were separated by gel electrophoresis, transferred to PVDF and visualized by 
phorphorimaging.  Next, the same membrane was immunoblotted with pT174/pS176 
phospho-caspase-3 antibodies. 
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2.4 DISCUSSION 
 Evidence of a structural mechanism for phosphorylation-dependent protection of 
caspase substrates, as well as the protection of a wide variety of caspase targets by 
phosphorylation suggests a role for phosphorylation in the negative regulation of 
apoptosis (9,25,32).  Perhaps the most pertinent protein kinase that indirectly regulates 
the cleavage of caspase substrates by phosphorylation is CK2.  CK2 is over-expressed in 
human cancers, participates in anti-apoptotic signaling, is constitutively active, and has a 
consensus motif that, like caspases, shows preference for acidic amino acids (33).  
Therefore, we were prompted to undertake the first bioinformatics analysis of clustered 
CK2 and caspase motifs and, in doing so, identified 64 proteins previously reported to 
have at least one of the predicted post-translational modifications.  One protein, MST4, 
had reports of both modifications, but upon further literature review it was clear that its 
suitability as a caspase substrate was controversial, and so was omitted from being a high 
priority candidate (34,35).  With no candidates known to be both cleaved by caspases and 
phosphorylated in cells, we opted to focus on putative substrates previously reported to 
have at least one of the predicted post-translational modifications and/or a bona fide role 
in apoptotic signaling upon caspase-mediated cleavage and identified caspase-3 itself.   
 The significance of identifying regulatory phosphorylation sites on caspase-3 is 
underscored by its critical role in the apoptotic cascade (Figure 2A).  The extrinsic and 
intrinsic apoptotic pathways both converge on caspase-3, where considerable evidence 
suggests that caspase-3 is the primary executioner caspase responsible for carrying out 
the demolition phase of the late apoptotic response (36-38).  Caspase-3 is subject to 
genetic alterations in cancer, including deletions, which abolish expression in MCF-7 
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breast cancer cells or point mutations in HL60/ADR cells that impair activation (39-41).  
In both instances, inhibition of caspase-3 activation diminishes the apoptotic response to 
chemotherapeutic agents, and sensitivity to cytotoxic drugs is rescued by expression of 
wild-type caspase-3, suggesting that post-translational modifications that act to block 
caspase-3 activity may also be detrimental to an apoptotic response.  Along these lines, a 
number of other post-translational modifications have been identified as contributors to 
the regulation of caspase-3, including ubiquitination (42), nitrosylation (43), and 
glutathiolation (44).  That CK2 blocks caspase-3 activation in vitro highlights a novel, 
albeit still theoretical, CK2 substrate that could perpetuate an anti-apoptotic signal.  
Kinetic studies revealed that caspase-3 is preferentially phosphorylated in the 
absence of the regulatory CK2! subunit, and that CK2 displays better kinetic parameters 
against caspase-3 than "-casein and calmodulin.  Interestingly, CK2 has hundreds of 
known substrates, but only a small fraction – Calmodulin, CapZ, S100B and NKX3.1 – 
have shown reduced phosphorylation in the presence of CK2! (6,19,30,45,46).  One 
postulation for the inhibitory effect of CK2! on a subset of substrates is that an acidic 
stretch on ! (amino acids 55-64) binds the catalytic subunit and partially occludes 
substrate binding (47,48).  Under this model, relaxation of restricted substrates can be 
achieved with polyamines that act by binding to and competing CK2!(55-64) off of the 
catalytic subunit, thereby rescuing substrate phosphorylation.  That poly-L-lysine 
treatment of the holoenzyme permitted caspase-3 phosphorylation suggests that the 
structural/binding features governing phosphorylation of other substrates of CK2 
inhibited by CK2!, such as calmodulin, may also dictate phospho-transfer onto caspase-
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3.  Along these lines, in both instances the presence of CK2! appears not to affect Km, 
but instead catalytic efficiency.  
 The development of a phospho-caspase-3 antibody represents the first biomarker 
for a CK2 substrate phosphorylated preferentially by the free catalytic subunit.  In this 
regard, the cellular function of catalytic CK2 devoid of CK2! remains relatively 
unexplored.  One major component of this is the extremely tight interaction between the 
regulatory and catalytic subunits (49), and a critical role in cell viability for CK2! that 
makes knockdown or knockout studies impractical (50).  The CK2 holoenzyme, made up 
of a CK2! dimer core bound to two catalytic subunits, only dissociates under denaturing 
conditions in vitro (51).  It seems to follow that unless the regulatory and catalytic 
subunits are excluded from one another, are actively dissociated, or are disproportionally 
expressed, the holoenzyme will form in cells.  Despite the tight association between 
CK2" or "# and !, evidence for free catalytic functionality in cells has been observed.  
The phosphorylation of calmodulin at the sites phosphorylated in vitro by CK2 were 
identified from rat liver (52).  In a related vein, evidence for misbalanced expression 
between the catalytic and regulatory subunits has been observed in breast (53) and head 
and neck cancers (54).  While the absolute levels of catalytic and regulatory CK2 were 
not measured in these samples, it is tempting to speculate that sub-stoichiometric 
amounts of CK2! preclude holoenzyme formation and drive free-catalytic specific 
functions.  Indeed, in Chapter 3, we aim to expand on these studies by utilizing our 
antibodies to examine the presence of free-catalytic CK2 in HeLa cells, and test the 
hypothesis that caspase-3 phosphorylation blocks apoptotic progression.    
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CHAPTER 3 – CHARACTERIZING THE CONVERGENCE OF PROTEIN 
KINASE CK2 AND CASPASE-3 REVEALS ISOFORM-SPECIFIC 
PHOSPHORYLATION OF CASPASE-3 BY CK2!": IMPLICATIONS FOR THE 
PATHOLOGICAL ROLES OF CK2  
 
3.1 INTRODUCTION 
Protein kinase CK2 is a ubiquitously expressed, highly conserved, constitutively 
active Ser/Thr kinase implicated in a plethora of cellular functions, including cancer 
progression (1).  High transcript expression (2,3), protein levels and kinase activity drive 
the pathological functions of CK2 in a number of human tumors and lymphomas 
(reviewed in (4)).  Indeed, this causative role for CK2 in transformation was observed in 
mice where tissue-specific overexpression of CK2! in breast and T-cells increased 
cancer burden (5,6).  As such, interest in CK2 as a target for cancer therapeutics has 
swelled of late, with the number of patents filed for CK2 inhibitors greatly increasing in 
recent years (7) and one inhibitor, CX-4945, even reaching clinical trials (8).  Implicit in 
understanding how CK2 inhibition can be most successfully translated to the clinic will 
be a careful dissection of CK2 function in disease.  Interestingly, recent studies have 
observed mis-balanced expression of the CK2 subunits in breast (9) and head and neck 
cancer (10), though how the relative levels of different subunits can impact disease 
progression remains largely unexplored.    
The two catalytic subunits of CK2 – CK2! and !" – are almost 88% identical 
within their catalytic domain, but exhibit divergent C-termini (11-14).  Not surprisingly, 
CK2! and !" display a shared minimal consensus phosphorylation site of S/T-X-X-D/E, 
 96 
suggesting that isozyme-specific, cellular functions/substrates are governed through 
subtle regulatory processes.  The unique of CK2! C-terminus has a number of mitotic 
phosphorylation sites and dictates specific interactions with Pin-1 and the mitotic spindle 
(15,16), but its catalytic domain also appears able to govern isozyme-specific interactions 
with CKIP-1 (17), PP2A (18), and a tighter interaction with the CK2" subunit compared 
to CK2!# (19).  Interestingly, while CK2" generally promotes phosphorylation of CK2 
substrates by increasing thermal stability, a small subset of targets – most notably 
calmodulin – are phosphorylated only in the absence of CK2" (20,21).  Despite a 
divergence in binding affinities between CK2" and CK2! or !#, the phosphorylation of 
substrates specific to the catalytic form of CK2 has not been systematically investigated 
in cells.  Furthermore, the observation that CK2" modulates substrate specificity may be 
particularly important with respect to CK2-related disease pathology, as a high 
CK2!:CK2" ratio drives epithelial-to-mesenchymal transition in human breast cancer (9) 
and transgenic mice that over-express only CK2! in the mammary gland are more prone 
to adenocarcinomas than control litter mates (5).  
The functional consequence of CK2 over-expression in human cancer remains 
enigmatic, likely due to the huge number (thousands) of substrates predicted to be 
phosphorylated by CK2 (22).  With respect to the cancer promoting functions of CK2, an 
anti-apoptotic role has been observed in a number of different studies (reviewed in (4)).  
Interestingly, CK2!#-/- mice display a hyper-apoptotic phenotype in spermatocytes (23) 
and forced expression of kinase-inactive CK2!# in U2-OS cells leads to defects in growth 
(24), but the cancer/CK2 literature remains largely biased to CK2!.  Mechanistically, a 
number of CK2 substrates, such as Bid (25)and YY1 (26), are also caspase substrates, 
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and are phosphorylated proximally to their scissile bond such that phosphorylation blocks 
both caspase cleavage, and the progression of apoptosis (reviewed in (27)).  This 
phenomena appeared phenotypically relevant to CK2 over-expression and cancer 
progression, so we previously explored the ability of CK2 to phosphorylate caspase 
substrates en masse proximally to their scissile bond, and identified the caspase-3 
zymogen as a lead candidate (28).  Furthermore, we found that caspase-3 was 
phosphorylated by recombinant CK2 catalytic subunits at the residues directly flanking 
the scissile bond that directs cleavage and caspase-3 activation.  Phosphorylation at these 
positions blocked caspase-3 cleavage by caspase-8 and -9 in vitro, validating our 
predictive strategy for identifying CK2 substrates that experience differential caspase-
mediated degradation that depends on phosphorylation.  
Given the importance of caspase-3 in the apoptotic response, we developed 
phospho-specific antibodies and employed systematic over-expression of the different 
forms of CK2.  We found that caspase-3 phosphorylation was specific for CK2!" in cells, 
but not in vitro kinase assays, and that the catalytic domain drove this preference.  
Furthermore, we show that CK2# negatively regulates caspase-3 phosphorylation, though 
the isozymic specificity was not a result of differential binding between ! and !" to 
endogenous CK2#.  Instead, our data support a model by which the free catalytic form of 
CK2! and !" are differentially regulated by a non-CK2# mechanism that differentially 
controls substrate access. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture and transfections 
 98 
HeLa (tet-Off) cells (Clontech) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% FBS, penicillin (100 U/mL), and streptomycin (100 
mg/mL) on 10-cm dishes.  Cells were transfected using 40 µg of total plasmid DNA via 
the calcium phosphate method (29).  For phosphatase inhibition studies, cells were 
treated with okadaic acid (Bioshop). 
 
3.2.2 Plasmid Construction 
CK2!-HA, CK2!"-HA, caspase-3-FLAG (C163A), caspase-3-his (C163A) and 
myc-CK2!" were prepared as described elsewhere (28,30).  CK2!-HA (1-45 CK2!") and 
CK2!-HA (300-350 CK2!") were constructed by first subcloning CK2!-HA from 
pRC/CMV into pet28a using HindIII and ApaI. CK2!"-HA was cut with BstBI / Bsu36I, 
to obtain the 1-45 amino acid fragment of CK2!", and ligated into the pet28a-CK2!-HA.  
This subclone was then moved back to pRC/CMV using HindIII / XbaI.  For 300-350 
CK2!", CK2!"-HA was ligated into pRC/CMV-CK2!-HA after digestion with Bsu36I 
and ApaI.  45-300 CK2!" was cloned using overlapping DNA sub-fragments generated 
by PCR reactions with T7 (F 5"-TAA TAC GAC TCA CTA TAG GG-3") and reverse 5"-
CCC CGA CCA AGT TTT CGA ACC AGC TGG TAG TCA TC-3" (for 1-45 CK2!), 
forward 5"-GAT GAC TAC CAG CTG GTT CGA AAA CTT GGT CGG GG-3" and 
reverse 5"-GTC CAG GAA ATC CAA GGC CTC AGG GCT GAC AAG GTG-3" (for 
45-300 CK2!") and forward 5"-CAC CTT GTC AGC CCT GAG GCC TTG GAT TTC 
CTG GAC-3" and Sp6 (R 5"-CAG CGA GCT CTA GCA TTT AGG TGA CAC TAT 
AG-3") (for 300-391 CK2!-HA).  Sub-fragments were gel purified, mixed, PCR 
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amplified for 2 cycles, amplified for another 20 cycles with T7 and Sp6, ligated into 
pCR-BLUNT, and cloned back into pRC/CMV using HindIII and ApaI. Caspase-3-
FLAG-NLS-(C163A) was generated by performing PCR reactions on caspase-3-FLAG-
(C163A) with T7 (F) and a reverse primer that included an NLS (nuclear localization 
sequence) tag (PKKKRKV) and a XhoI restriction site downstream of the FLAG tag (5!-
TTC TCG AGC TAC ACC TTA CGC TTT TTC TTT GGC TTG TCG TCG TCG TCC 
TT-3!).  The PCR product was ligated into PCR-Blunt, digested out using BamHI and 
XhoI and ligated into pCDNA3.1(+).  All constructs were sequence verified.   
 
3.2.3 Cell lysis, immuno-precipitations and Western blotting 
Cells were lysed in NP-40 alternative lysis buffer [1% NP-40 alternative, 150 mM 
NaCl, 50 mM Tris (tris(hydroxymethyl)aminomethane) (pH 7.5), leupeptin (10 µg/mL), 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), pepstatin (10 µg/mL), aprotinin (5 
µg/mL), 25 mM NaF, 1 µM okadaic acid and 1 mM sodium orthovanadate].  Lysates 
were sonicated 2 " 5 s, spun for 15 minutes at 4°C at 13 000 " g, and protein 
concentrations determined by bicinchoninic acid (BCA) assay (Thermo Scientific).  For 
immuno-precipitations, 0.5 – 2 mg of lysate was tumbled 4 µg of anti-Flag M2 (Sigma) 
and 30 µL of protein A/G sepharose beads (GE Healthcare) for 1 H.  For CK2# immuno-
precipitations, anti-CK2# sera (31) was tumbled with 200 ug of lysate for 1 H, then 30 
µL of protein A sepharose beads added and tumbled for an additional hour.  Endogenous 
caspase-3 was immuno-precipitated from 10 mg of lysate with 5 µg of anti-caspase-3 
(BD Biosciences clone 19) and 30 µL of protein A/G sepharose beads.  Immune-
complexes were washed 2 " 500 µL NP-40 alternative lysis buffer and proteins separated 
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by 12% SDS-PAGE, transferred to PVDF membranes and blotted using antibodies to: 
caspase-3 (BD biosciences clone 19), HA (3F10, Roche), PARP (Cell Signaling 
Technology), Vinculin (Sigma), phospho-caspase-3 (pT174/pS176) (32), CK2! (33), 
CK2!" (33), CK2# (33), SAV-680, GAM-680 and GAR-800 (LI-COR Biosciences).  
Quantitation of western blots was performed using Odyssey software (version 3.0) from 
LI-COR Biosciences. 
 
3.2.4 Nuclear and Cytoplasmic fractionation of HeLa cells 
CK2-HA was assessed in different cellular departments using the NE-PER 
Nuclear-Cytoplasmic extraction kit (Thermo Scientific).  Briefly, transfected HeLa cells 
were lysed and subsequently treated according to manufacturer’s recommendations in 
order to obtain purified whole cell extracts of nuclear or cytoplasmic origin.  Using a 
BCA protein assay kit (Thermo Scientific), 40 or 80 µg of whole cell extract was loaded 
onto 10 or 15 % SDS-PAGE gels and the resolved proteins were transferred to PVDF 
membrane for subsequent Western Blotting using monoclonal and polyclonal antibodies 
targeted against caspase-3, phosphorylated caspase-3, CK2!, CK2!’, and CK2#.  
Vinculin and PARP antibodies were used to monitor for purity of each cellular 
compartment. 
 
3.2.5 Kinase assays 
Kinase assays using recombinant proteins were performed largely as described in 
(28).  Caspase-3-his-(C163A) and catalytic subunits of GST-tagged CK2 were purified 
from bacterial sources as previously noted in (28) and (34), respectively.  Holoenzyme 
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preparations of CK2 were prepared by expressing catalytic and regulatory subunits of 
CK2 in separate preparations of E. coli, mixing the pellets during lysis, and isolating the 
holoenzyme by purification on a heparin column and then by size exclusion 
chromatography.  The activity of purified CK2 was characterized (34) by performing 
kinase assays with the substrate peptide RRRDDDSDDD (EZBiolab) (100 µM) so that 
equal units of enzyme could be added to kinase assays containing 1 µg of recombinant 
caspase-3-his-(C163A).  All assays were performed in 50 mM Tris (pH 7.5), 150 mM 
NaCl, 10 mM MgCl2, 100 µM ATP and 0.2 µCi [!-32P]ATP per 30 µL of reaction. 
When using cell extracts as the kinase source, lysates were prepared by scraping 
cells into ice-cold 50 mM "-glycerophosphate, 1.5 mM EGTA, leupeptin (10 µg/mL), 0.1 
mM phenylmethylsulfonyl fluoride (PMSF), pepstatin (10 µg/mL), aprotinin (5 µg/mL), 
1 µM okadaic acid and 1 mM sodium orthovanadate, followed by sonicating for 2 # 5 s 
and removing debris by centrifuging for 15 minutes.  After a Bradford assay, kinase 
assays were performed using 5 µg of lysate, 100 µM RRRDDDSDDD or 100 µM of 
eIF2" peptide (MSGDEMIFDPTMSKKKKKKKKP) in 50 mM Tris (pH 7.5), 150 mM 
NaCl, 10 mM MgCl2, 100 µM ATP and 0.2 µCi [!-32P] ATP per 30 µL of reaction.  
Assays were performed for 5 or 10 minutes, to verify linearity, and stopped by spotting 
on P81 paper.  32P was detected using a STORM phosphorimager and quantitated with 
ImageQuant TL software.   
 
3.2.6 Lysate dephosphorylation assay 
Phospho-caspase-3 was generated by phosphorylating caspase-3-his (C163A) 
with excess GST-CK2$ in 150 mM NaCl, 50 mM Tris (pH 7.5), 10 mM MgCl2, and 100 
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µM ATP.  Reactions were diluted 1/50 into 100 µg of lysate such that 1 µg of phospho-
caspase-3 was in each reaction.  Fifty µM of the CK2 inhibitor TBBz (calbiochem) was 
included to stop the kinase assay.  500, 50 or 5 nM of okadaic acid (Bioshop) or 
tautomycin (calbiochem) was also added to the lysate dephosphorylation assay.  DMSO 
was used as a carrier control. 
3.2.7 Microscopy 
Cells were grown on sterile glass cover slips, washed with PBS, fixed with 3.7% 
paraformaldehyde for 30 minutes, washed in 0.1 M glycine for 20 minutes at 37°C and 
permeabilized with 0.1% Triton X-100 for 5 minutes.  All solutions were made in PBS 
and incubations were performed at room temperature unless otherwise stated.  After 
permeabilization, cells were incubated for 45 minutes with a 1:50 dilution of anti-
caspase-3 in 5% BSA/PBS, washed 3! PBS and then incubated with GAM-AlexaFluor 
488 (1:1000) (Invitrogen) for 45 minutes.  Samples were stained with Hoechst 33258 
before final PBS washes and mounting with ProLong Gold (Invitrogen).  Slides were 
visualized using an Axiovert inverted fluorescence microscope. 
 
3.3 RESULTS 
3.3.1 The catalytic domain of CK2"#  directs phosphorylation of caspase-3  
We previously reported that caspase-3 is phosphorylated by recombinant CK2 at 
T174 and S176 – a phosphorylation event that mitigates activation by upstream caspases 
(28).  To further investigate caspase-3 phosphorylation, we raised antibodies against 
synthetic peptides of the doubly phosphorylated caspase-3 peptide (32) and 
systematically modulated expression of the CK2 catalytic isoforms to test 
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phosphorylation of caspase-3-FLAG-(C163A).  Interestingly, despite equal expression 
and activity of CK2!-HA and !"-HA, caspase-3 phosphorylation was induced only in the 
presence of CK2!"-HA (Figure 3.1A, Supplemental Figure 3.1) (11-14).  To the best of 
our knowledge, this is the first demonstration that the cellular isozymes of CK2 can 
exhibit different activities against a substrate – an observation especially remarkable 
given the 86% identity within their catalytic domain (residues 45-312) (Figure 3.1B).  In 
an effort to avoid unwanted caspase-3 activation, we utilized caspase-3-FLAG-(C163A) 
which replaces the catalytic cysteine with alanine.  We found that caspase-3-FLAG was 
less efficiently phosphorylated than caspase-3-FLAG-(C163A) (hereafter referred to as 
C3-FLAG) and so emphasize the characterization of isozymic specificity in this study 
(Supplemental Figure 3.1C).   
To identify the sequence determinants responsible for isozymic preference of 
caspase-3 phosphorylation, we constructed CK2! / !" chimeras whereby three different 
segments of CK2!" were swapped into CK2!-HA (Figure 3.1 C, upper panel).  Segments 
consisted of the N-terminus (1-45), the catalytic domain that contains the most of the 
conserved subdomains for kinase family members (45-300), and the divergent C-
terminus (300-350).  Upon co-transfection of the different chimeras with C3-FLAG, we 
were surprised to learn that the catalytic domain of CK2 dictates specificity for !", as 
only CK2!-HA constructs containing amino acids 45-300 of CK2!" showed 
phosphorylation of caspase-3 greater than CK2!-HA (Figure 3.1C).  Furthermore, though 
considerable divergence of the C-terminus exists, it does not play a role in dictating 
substrate specificity in this instance.  Interestingly, amongst the primary sequence 
differences between the catalytic domain of CK2! and !" is the conspicuous presence of 
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Figure 3.1 – C3-FLAG is phosphorylated by CK2a!-HA, but not CK2"-HA in cells.  (A) 
HeLa-Tet-Off cells were transfected with C3-FLAG and CK2"-HA or CK2"!-HA, lysed, 
and C3-FLAG isolated by immunoprecipitation.  Lysates and immunoprecipitations were 
blotted as indicated.  Densitometric analysis represents the ratio of pC3:HA signal with 
error bars generated from the standard deviation of 3 independent experiments.  (B) 
Sequence alignment of human CK2" (above) and "! (lower).  Residues that are not 
identical in CK2"! are indicated and the segments used for chimeras are highlighted: 
residues 1-45 in blue, 45-300 in green, and 300-350 in purple and the motif responsible 
for PP2A binding by CK2" in red.  (C and D) Cells were co-transfected with CK2 
chimeras and C3-FLAG, lysed, and C3-FLAG enriched by immunoprecipitation.  Lysates 
and immunoprecipitated samples were blotted as indicated. 
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a highly conserved HEHRKL motif in CK2! that is absent in CK2!" and previously 
reported to be required for binding PP2A (18) (Figure 3.1B).  Multiple authors have 
hypothesized that this region could serve as a distinguishing feature for PP2A interaction, 
and isoform specific functions of catalytic CK2 (35,36).  Therefore, we hypothesized that 
a PP2A/CK2!-HA interaction could deter C3-FLAG phosphorylation, and so aimed to 
test this by swapping the CK2!" HQQKKL sequence into CK2!-HA and probing for C3-
FLAG phosphorylation.  However, CK2!-HA(HQQKKL) was unable to rescue C3-
FLAG phosphorylation, arguing against a PP2A-CK2! complex that dictates isoform 
specific phosphorylation of caspase-3 (Figure 1D).   
 
3.3.2 CK2#  controls caspase-3 phosphorylation  
The regulatory CK2# subunit is capable of controlling substrate specificity 
despite having no known catalytic activity (37).  Most substrates are phosphorylated 
more readily by the CK2 holoenzyme in vitro – a characteristic likely driven by the 
improved stability of CK2! or !" in complex with CK2# – though a small subset of 
substrates, most notably calmodulin, are phosphorylated only in the absence of CK2# 
(20,21).  Interestingly, CK2!" binds CK2# 10$ more weakly in vitro than does CK2! as 
a result of altered folding of the #4/#5 loop – a structural feature within the catalytic 
domain that makes significant contacts with CK2# (19).  Therefore, we were driven to 
test first the hypothesis that CK2# regulates phosphorylation of caspase-3, and second, 
that the differential affinity for CK2# and the two catalytic subunits might drive isozymic 
substrate preferences.  Upon co-transfection of myc-CK2# with either catalytic isozyme 
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and C3-FLAG, we found that CK2! dramatically attenuated C3-FLAG phosphorylation 
by CK2"#-HA and further reduced the low level of phosphorylation achieved by CK2"-
HA expression (Figure 3.2A).  CK2! also blocked phosphorylation of C3-FLAG by myc-
CK2"# in U2-OS cells (data not shown).  The ability of CK2! to block caspase-3 
phosphorylation in cells prompted us to test all forms of CK2 for their ability to 
phosphorylate caspase-3 in kinase assays using recombinant proteins.  Figure 3.2B shows 
that isozymic specificity was lost when in vitro kinase assays were performed, but the 
inhibitory effect of CK2! remained.  Furthermore, like other CK2 substrates that are 
phosphorylated only in the absence of CK2!, treatment of the holoenzyme with 
polyamines resulted in hyperphosphorylation of caspase-3 in in vitro kinase assays (data 
not shown).  
 
3.3.3 Endogenous CK2!  binds CK2"-HA and CK2"#-HA equally and 
stoichiometrically in lysates  
In an effort to investigate if pools of CK2"# devoid of CK2! were forming after 
over-expression, we utilized a CK2 substrate peptide that displays little preference for 
catalytic subunits or the holoenzyme (DSD in Figure 3.3A) and an eIF2! substrate 
peptide that is specific for the holoenzyme (38).  An increase in the DSD:eIF2! ratio 
indeed suggested an increase in CK2!-free myc-CK2"# (Figure 3.3A).  Of particular 
interest was the observation that C3-FLAG phosphorylation actually preceded 
measurable differences in DSD:eIF2! phosphorylation, suggesting that our assay either 
lacks the required sensitivity to detect small changes in the ratio of free catalytic subunits 
and holoenzyme  or that a cellular, CK2!-refractory population of CK2"# becomes 
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Figure 3.2 – CK2! inhibits caspase-3 phosphorylation.  (A) Cells were co-transfected 
with the indicated CK2 constructs and C3-FLAG.  Lysates were immunoprecipitated with 
anti-FLAG to isolate caspase-3, separated by SDS-PAGE and immunoblotted as 
indicated.  (B) Equal units of the indicated forms of recombinant CK2 were used in 
kinase reactions with caspase-3-His (C163A) and ATP-"-P32.  Reactions were separated 
by SDS-PAGE, the gels dried, and visualized using a phosphorimager. 
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Figure 3.3 – Investigation of CK2 form in cell lysates reveals a predominately 
holoenzyme form.  (A) Cells were transfected with C3-FLAG and varying amounts of 
myc-CK2!", and harvested after 40 h.  Lysates and FLAG immunoprecipations were 
probed as indicated.  Lysates were assessed in kinase assays along with two CK2 
substrate peptides.  The DSD peptide (RRRDDDSDDD) is phosphorylated by both 
catalytic free CK2 and holoenzyme while the eIF2# peptide 
(MSGDEMIFDPTMSKKKKKKKKP) is phosphorylated exclusively by the CK2 
holoenzyme.  Graphs represent the ratio of DSD:eiF2# activity with error bars 
representing the standard deviation of triplicate kinase assays.  (B) Cells transfected with 
CK2!-HA or CK2!"-HA were harvested and subjected to consecutive rounds of 
immunoprecipitation using a CK2# antibody or mock control.  Both the supernatant from 
the immunoprecipitation and the immunoprecipitation itself were western blotted for HA 
and CK2# as indicated. 
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complexed with CK2! upon cell lysis.  In support of the latter, we also observed 
complete complex formation between HA-tagged CK2 catalytic subunits with 
endogenous CK2! (Figure 3.3B).  Here, lysates subjected to immunoprecipitation with 
CK2! antibodies show over 90% depletion of CK2!, CK2"-HA and CK2"#-HA after 
two rounds of immunoprecipitation, with no substantial difference between the catalytic 
subunits remaining in the supernatant.  That HA-tagged CK2" and "# bound endogenous 
CK2! further reinforces the notion that both isozymes of ectopic CK2 are fully 
functional, and that the difference in caspase-3 phosphorylation may arise from 
differences in the cellular regulation of CK2"-HA versus CK2"#-HA that extend 
exclusively beyond regulation by CK2!. 
We found that endogenous CK2 was unable to generate C3-FLAG that is reactive 
with phospho-caspase-3 antibodies, suggesting that in HeLa cells CK2"# is entirely 
holoenzyme (Figure 3.3A, Lane 1).  CK2 holoenzyme-mediated phosphorylation of non-
holoenzyme substrates can be stimulated by polyamines in in vitro kinase assays and by 
ODC1 (ornithine decarboxylase 1) – the rate limiting enzyme of spermine synthesis – 
over-expression in cells (39-41).  However, we found no stimulation of caspase-3 
phosphorylation by endogenous CK2 upon ODC1 over-expression (data not shown).  
 
3.3.4 Nuclear, endogenous CK2"#  is bound to CK2!    
We were next interested in testing the effect of C3-FLAG localization on 
phosphorylation.  The caspase-3 zymogen was previously reported to be a predominately 
cytoplasmic protein (42) and, indeed, was found to mostly localize outside the nucleus in 
our studies (Figure 3.4A, upper panels).  Interestingly, multiple reports have found that 
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Figure 3.4 – Redirecting C3-FLAG to the nucleus does not alter the relative levels of 
phosphorylation.  (A) Cells were transfected with C3-FLAG or C3-FLAG-NLS and then 
transferred to glass cover slips in 6-well dishes.  Twenty-four hours after transfection, 
cover slips were stained using caspase-3, which was detected by Alexa-Fluor GAM-488, 
and Hoechst 33258, mounted on microscope slides and analyzed on an inverted 
fluorescence microscope.  (B) Cells were transfected with CK2!-HA or CK2!"-HA and 
the cytoplasmic and nuclear fractions separated and blotted as indicated.  PARP was used 
as a marker for nuclear separation and Vinculin for cytoplasmic.  (C) Cells were co-
transfected with C3-FLAG-NLS and the indicated CK2 construct, then harvested.  FLAG 
immunoprecipitations and lysates were immunoblotted as indicated.  CTRL denotes the 
empty vector lane.    
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while CK2 substrates are distributed throughout many cellular compartments (reviewed 
in (43,44)), there is a precedent for nuclear CK2 to be the predominant form (45).  We 
found the CK2-HA localized to both cytoplasmic and nuclear fractions in HeLa-tet off 
cells and predicted that C3-FLAG was only probing the cytoplasmic fraction of CK2 for 
the CK2!-free form (Figure 3.4B).  Furthermore, Filhol et al. (2003) observed GFP-
CK2" localization as exclusively nuclear in the absence of ectopic CK2! and so we 
hypothesized that the free catalytic form of CK2 is most likely to occur in the nucleus 
(46).  To test this hypothesis, we included a nuclear localization signal (NLS) on the C-
terminal end of our C3-FLAG construct that successfully redirected caspase-3 to the 
nucleus (Figure 3.4A, lower panels).  Upon transfecting C3-FLAG-NLS alone, or in 
combination with CK2"- or "#-HA, we found that C3-FLAG-NLS phosphorylation 
mirrored that observed with caspase-3-FLAG; there was no measurable phosphorylation 
in the absence of ectopic CK2, minimal phosphorylation by CK2"-HA, and robust 
phosphorylation by CK2"#-HA (Figure 3.4C).  We concluded that these data support a 
model that impaired phosphorylation of C3-FLAG by CK2"-HA is not dictated by 
nuclear versus cytoplasmic localization, and that nuclear, endogenous CK2"# is 
predominately holoenzyme in HeLa cells.  
 
3.3.5 Okadaic acid abolishes the isozymic preference of C3-FLAG phosphorylation   
The observation that endogenous CK2 was insufficient to phosphorylate both 
cytoplasmic and nuclear C3-FLAG led us to believe that either cellular CK2"# was fully 
holoenzymatic, or that C3-FLAG was being actively dephosphorylated.  Indeed, when 
recombinant phosphorylated caspase-3 was incubated with cellular extracts lacking 
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phosphatase inhibitors, a marked decrease in phosphorylation was observed indicating 
active dephosphorylation (Figure 3.5A).  Furthermore, dephosphorylation was more 
sensitive to okadaic acid (Ki for PP2A < PP1) than tautomycin (Ki for PP2A > PP1), 
suggesting PP2A as the responsible phosphatase.  In cells, okadaic acid was unable to 
induce C3-FLAG phosphorylation by endogenous kinases further suggesting that 
endogenous CK2!" is fully bound to CK2# (data not shown).  Interestingly, okadaic acid 
also completely rescued phosphorylation by CK2!-HA to levels comparable to those 
seen with CK2!"-HA (Figure 3.5B), but was blocked by myc-CK2# (Figure 3.5C).  
These data support a model by which CK2!-HA is free of endogenous CK2# and, 
therefore, catalytically competent to phosphorylate C3-FLAG, but is restricted access to 
C3-FLAG by some mechanism that is relieved by okadaic acid.  Finally, we were 
interested in testing if endogenous caspase-3 was phosphorylated by ectopic CK2!" and 
found that phosphorylation occurred in the presence of okadaic acid (Figure 5D).  
Therefore, our results support the conclusion that caspase-3 phosphorylation could be 
physiologically relevant in tissues or pathologies in which non-holoenzyme CK2!", or 
potentially CK2!, and high levels of caspase-3 are present and in the cytosol.  
Furthermore, we expect that transfection of C3-FLAG can be used as a tool to aid in the 
identification of cell culture models that have free catalytic CK2!", for which no bona 
fide experimental systems currently exist.     
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Figure 3.5 – Exclusion of CK2!-HA from C3-FLAG phosphorylation is not governed by 
endogenous CK2" in HeLa cells.  (A) Recombinant His-tagged caspase-3-(C163A) was 
fully phosphorylated by GST-CK2!.  Reactions were quenched by the addition of the 
CK2 specific inhibitor TBBz, and added to HeLa lysates harvested in the absence of 
phosphatase inhibitors.  Okadaic acid or tautomycin at concentrations of 50, 5 or 0.5 nM 
was added to the reaction as indicated.  (B-D) HeLa cells were transfected with C3-
FLAG and the indicated constructs except in (D), where endogenous caspase-3 was being 
probed.  After a 24 hour recovery, cells were treated with or without 1 uM okadaic.  
FLAG or caspase-3 immunoprecipitations and lysates were blotted as indicated.  
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3.4 DISCUSSION 
Misbalanced expression of CK2 subunits in cancer has been observed, but the 
hypothesis that the particular CK2 form can dictate specific phenotypes through 
phosphorylation of different substrates remains largely unexplored prior to this work.  In 
this study we provide direct evidence that CK2!" has a specific cellular substrate that is 
restricted from CK2! in both the cytoplasm and the nucleus.  Furthermore, because C3-
FLAG phosphorylation by CK2!-HA could be rescued by okadaic acid, and further 
blocked by myc-CK2# (Figure 5B and C), suggests that the isozymic substrate preference 
is not dictated by endogenous CK2# in cells – an unanticipated, additional level of 
regulation not seen before.  CK2!" specific functions have previously been observed, the 
most notable of which is the finding that CK2!" knock-out mice exhibit a hyper-
apoptotic phenotype in spermatocytes (23), and that forced expression of kinase-inactive 
CK2!" in U2-OS cells resulted in proliferation defects (24).  Furthermore, Orlandini et al. 
(1999) highlighted the oncogenic activity of CK2!" in experiments that demonstrated co-
operativity with Ras in the transformation of rat fibroblasts (47).  In a related vein, Li et 
al. (2006) showed that NKX3.1 has a decreased half-life upon CK2!" knock-down, or 
mutation of phospho-acceptors to alanine, and that NKX3.1 phosphorylation was 
mediated by CK2!" devoid of CK2# in in-gel kinase assays (48).  By identifying a CK2 
substrate preferentially phosphorylated by CK2!", we believe our studies reinforce the 
notion that CK2!" has cellular functions distinct from CK2!. 
Reasoning that caspase-3 phosphorylation is dictated by differences in sequence 
between the two isozymes, we generated chimeras and observed a rescue of CK2!-
mediated phosphorylation of caspase-3 when constructs expressed CK2!" residues 45-
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300.  What is striking is that a comparison of the CK2! and !" sequences reveals the 
internal catalytic portion as actually the most conserved – residues 1-45 are 74% 
identical, 45-300 are 88% identical and 300-350 are 56% identical.  Interestingly, the 
catalytic domain of CK2! has previously been implicated in isoform specific 
interactions.  The Goldberg laboratory demonstrated that PP2A interacts with the 
HEHRKL motif within CK2! – an area with a cluster of divergence from CK2!" (Figure 
3.1B) – though we found that swapping the HQQKKL motif of !" into CK2! was unable 
to rescue C3-FLAG phosphorylation (18).  Similarly, this region has also been tested for 
regulating the CK2! specific binding to CKIP-1, but CK2!-E167Q was unable to disrupt 
CKIP-1 interaction, nor was CK2!"-Q168E able to promote binding to CKIP-1 (49).  The 
observation that residues 45-300 of CK2!", an area of 88% sequence identity and 93.3% 
sequence similarity, control C3-FLAG phosphorylation further reinforces the notion that 
subtle regulatory mechanisms must exist to differentially control these two isozymes.  
Collectively, the examples of the CKIP-1/CK2! interaction and caspase-3 
phosphorylation illustrate that despite extensive sequence conservation between the 
catalytic domain of CK2! and !", significant divergence exists and can drive unique 
functions.  
Structural variances that could impart isozymic specificity do occur in residues 
45-300 in the non-holoenzyme form of the catalytic subunits, but these differences also 
receive contributions from the N-terminus.  For example, the #4/#5 loop is constitutively 
open in CK2!" and is located at residues 95-114, but stabilization is in part mediated by 
residues 34-37 and thought to result from a unique proline in CK2!" at residue 32 (19).  
Interestingly, Pro92 is unique to CK2! and located just upstream of the #4/#5 loop, 
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though the changes that result from this divergence remain unknown.  Another structural 
variation occurs in the interdomain region – a segment responsible for co-ordinating 
binding with ATP and ATP-competitive inhibitors (residues 114-122 of CK2!").  This 
hinge is slightly collapsed in CK2!, but also correlates with a closed #4/#5 loop which, 
again, appears to receive structural contributions from the N-terminus.  Tyr116 and Ile117 
are not conserved in CK2! (His115, Val116) but how these residues contribute to 
differences in hinge region structure remain unknown.  Should the noted structural 
alterations be consistent with our chimeras, it is enticing to speculate that okadaic acid 
either governs protein-protein interactions or post-translational modifications of CK2! 
that can resolve this divergence.  With respect to the latter, a PHOSIDA search for unique 
post-translational modifications on ! and !" revealed that !" is acetylated on K97 (T96 
on CK2!) and CK2! phosphorylated on T127 (I128 on CK2!"), providing a putative 
mechanism that differentially controls CK2 catalytic isozymes (50).  Precedence for the 
former has been observed with v-src as okadaic acid treatment disrupts the v-src/Hsp90 
interaction (51).  CK2! interacts with Hsp90 (52,53), but if this interaction restricts 
access to CK2 substrates or is altered by okadaic acid remains speculative. 
 CK2# binds to CK2! and !" spontaneously in solution (54) with a low Kd 
(CK2!" - 45.5 $ 10-9 M, CK2! - 3.7 $ 10-9 M (19)) and will only dissociate under 
denaturing conditions (55).  The observation that CK2-HA bound endogenous CK2# in 
immunoprecipitation assays reinforced that holoenzyme was forming in our experimental 
system, but seemed at odds with C3-FLAG phosphorylation in cells.  We interpreted 
these data as support for an exclusion mechanism of catalytic CK2 from endogenous 
CK2# in cells that can be overcome by cell lysis, or over-expression of myc-CK2#.  That 
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endogenous CK2! bound ectopic catalytic CK2 upon lysis suggests the presence of 
excess CK2! in HeLa cells, which has also been observed in Burkitt’s lymphoma Ramos 
cells and hypothesized to occur in mouse brain and testes (56,57).  Therefore, our 
proposed mechanism holds that CK2 form is dictated not only by relative levels of 
catalytic and regulatory CK2, though this is definitely a contributing factor, but appears 
to be regulated by exclusion upon catalytic subunit expression.  Furthermore, our data 
suggests that the cellular form of CK2 cannot be investigated by procedures interrogating 
cell extracts for interaction between CK2! and " or "#.  In this sense, C3-FLAG 
represents the first phospho-specific antibody biomarker for non-holoenzyme activity of 
cellular CK2 that could aid in the identification of tissue culture model systems that 
contain CK2!-free populations of CK2"# and potentially CK2".  
Anecdotal evidence for free catalyic CK2 functions in cells has previously been 
observed, but a unifying mechanism for this form of CK2 in physiology and disease 
remains unclear.  Amongst the first proof for the CK2!-free form of catalytic CK2 in 
cells was the identification of the CK2 phosphorylation sites of calmodulin from rat liver 
(58).  As well, NKX3.1 is phosphorylated by CK2"# in in-gel kinase assays only in 
fractions that lacked CK2! and NKX3.1 protein levels are negatively correlated with 
both CK2 inhibitor treatment and CK2"# knockdown (48).  Finally, Deshiere et al. (2012) 
noted that the CK2"#:CK2":CK2! ratio varies across breast cancer samples, and that a 
higher CK2":CK2! ratio correlates with the expression of epithelial-to-mesenchymal 
transition markers (9).  Taken together with the demonstration that CK2 form can dictate 
substrate accessibility in cells, we propose that pathological function of CK2 will depend 
on subunit composition.  Furthermore, disambiguation of free catalytic, holoenzyme and 
 120 
isozyme specific functions together with the development of biomarkers for these 
processes should aid in identifying context specific treatments and combinatorial 
strategies. 
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3.6 SUPPLEMENT 
 
 
 
 
 
Supplemental Figure 3.1 – Companion to Figure 3.1.  (A) Cells were transfected as in 
Figure 1A, and washed 18 hrs post transfection.  Lysates were generated at the indicated 
timepoints followed by FLAG immunoprecipitation and western blotting as indicated.  
(B) Lysates from HeLa cells exhibiting equal amounts of CK2!-HA and CK2!"-HA 
were used for kinase assays with the CK2 specific substrate peptide RRRDDDSDDD.  
Error bars represent the standard deviation of triplicate reactions.  (C) Cells were 
transfected with myc-CK2!" and the indicated caspase-3 construct, washed after 18 hrs 
and allowed to recover for 24 hrs.  At this point lysates were generated, FLAG 
immunoprecipitations performed and samples western blotted as indicated. 
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CHAPTER 4 – AN UNBIASED, PROTEOMIC SCREEN REVEALS NOVEL 
CASPASE CLEAVAGE EVENTS POSITIVELY AND NEGATIVELY 
REGULATED BY SUBSTRATE PHOSPHORYLATION 
 
4.1 INTRODUCTION 
 Apoptosis is a cell death program integral in various biological processes such as 
tissue homeostasis and development, but also misregulated in disease (1).  Notably, the 
ability of cancer cells to evade apoptosis is considered a driving feature that imparts a 
cellular selective advantage and allows cells to persist inappropriately (2).  Major 
components of apoptotic evasion in cancer involve the misregulation of two classes of 
enzymes – protein kinases and caspases.  Kinases transfer phosphate from ATP to 
proteins to alter substrate function (3).  Activating mutations, amplifications, gene fusions 
and over-expression of oncogenic kinases represent an underlying basis of disease the 
offers therapeutic strategies (3).  In this way, inhibiting oncogenic kinases can lead to 
selective apoptotic induction of cancer cells.  Caspases, or cysteine-containing, aspartic-
acid-directed proteases, act as executioners of the apoptotic program by cleaving key 
structural and enzymatic proteins resulting in cellular demolition (4).  Not surprisingly, 
constrained caspase activity, by post-translational modifications or genetic mutations or 
deletions, can also contribute to the malignant phenotype by blocking apoptotic 
progression (5,6). 
Interestingly, numerous examples exist detailing the crosstalk between caspases 
and kinases as a major apoptotic regulatory mechanism (6,7).  One intriguing mode of 
controlling caspase activity is through phosphorylation of caspase substrates.  Anecdotal 
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examples exist whereby phosphorylation at P4, P2 and P1! (see Figure 4.1A for cleavage 
site nomenclature) can block cleavage (7).  As well, there is precedent for 
phosphorylation sites outside the caspase motif to regulate susceptibility to proteolysis.  
For example, phosphorylation of Acinus-S at S422 by Akt blocks its cleavage at D355 
(8).  Interestingly, phospho-dependent blocking of caspase-mediated proteolytic events 
can actually impact cellular phenotype; inhibitory phosphorylations on Bid, Presenilin-2 
and Acinus-S all obstruct caspase cleavage and apoptotic progression (8-11).  In this way, 
phospho-dependent regulation of caspase-mediated cleavage has been hypothesized as a 
global regulator of apoptotic progression, especially in the context of cancer where 
hyper-active, oncogenic kinases may act to increase phospho-site occupancy within 
caspase cleavage motifs (7).  Indeed, we previously tested this hypothesis using 
predictive, peptide match programs and identified CK2 phosphorylation sites on caspase-
3 that regulated its activation by caspase-8 and -9 (12, Chapter 2).   
To build on our predictive strategy, we devised an unbiased, proteomic 
methodology to identify novel proteins where phosphorylation regulates caspase 
cleavage.  To establish this approach, we measured the caspase degradome in the context 
of a native phospho-proteome and compared it to the degradome generated when lysates 
were first dephosphorylated with " phosphatase.  The advantage of this approach is that 
we can concurrently monitor the effects of phosphorylation sites on cleavage that are 
both local and distant from the scissile bond.  This latter point is important, as there is no 
way to predict how distant phosphorylation sites may affect caspase proteolysis.  To 
measure and identify these events, we utilized the N-terminomic workflow TAILS 
(terminal amino isotopic labeling of substrates) (13).  Comparative analysis of the 
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caspase degradomes from phosphorylated or dephosphorylated lysates revealed Yap1 and 
Golgin-160 as caspase substrates negatively regulated by phosphorylation.  Surprisingly, 
we also identified a number of caspase substrates whose cleavage is promoted by 
phosphorylation, and validated that MST3 behaves this way. 
Interestingly, during the course of our study, Dix et al. (2012) also found that 
phosphorylation at P3 can actually promote cleavage of caspase peptide substrates (14).  
These authors also obtained substantial evidence for phosphorylation occupancy 
throughout the caspase motif.  Therefore, spurred by the examples of the positive effect 
of phosphorylation on caspase cleavage, we undertook a systematic evaluation of the role 
of phosphorylation throughout the entirety of the caspase cleavage motif.  Along these 
lines, the primary amino acid sequence determinants for various caspases from P4 – P1! 
are well defined, but phospho-residues within this motif have only been anecdotally 
studied.  Furthermore, residues outside this region, at P5, P2! and P3! have recently been 
found to alter caspase -3 and -7 recognition (15), but have unknown determinant effects 
when phosphorylated.  To address these issues, we systematically walked phospho-Ser 
through the length of model caspase substrate peptides, and found that phosphorylation 
was generally inhibitory to caspase cleavage.  Therefore, taken together with our TAILS 
data, these results suggest that phosphorylation of caspase substrates promotes cleavage 
primarily through effects not related to the primary amino acid determinants.  
Furthermore, our studies demonstrate that N-terminomics approaches can be tailored to 
identify novel, hierarchical events controlling cleavage of caspase substrates. 
 
4.2 MATERIALS AND METHODS 
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4.2.1 Caspase degradome preparation 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% FBS, penicillin (100 U/mL), and streptomycin (100 mg/mL) on 10-cm 
dishes.  Cells were treated for 45 min with 1 µM okadaic acid (Bioshop), followed by 
lysis in 0.1 % CHAPS, 20 mM PIPES (pH 7.4), 100 mM NaCl, leupeptin (10 µg/mL), 0.1 
mM phenylmethylsulfonyl fluoride (PMSF), pepstatin (10 µg/mL), aprotinin (5 µg/mL), 
50 mM NaF, 1 µM microcystin and 1 mM sodium orthovanadate.  Cells were lysed by 
sonication with 2 pulses for 5 seconds each, and the samples subsequently cleared by 
ultracentrifugation at 13 000 ! g if samples were being used for western blot analysis, or 
140 000 ! g for samples being used for proteomic analysis.  Lysates were then exchanged 
into 100 mM HEPES (pH 7.0) 3 ! using 3 K cut-off buffer exchange filters (Amicon) to 
remove phosphatase inhibitors prior to lambda phosphatase treatment, and small 
molecule primary amines to permit complete dimethyl labeling of primary amines on 
proteins.  Protein concentration was assessed by a Bradford assay.  After buffer 
exchange, the sample was split in two, and diluted in 10 ! phosphatase buffer (see NEB 
supplier for details) and 5 ! caspase buffer (see above), and then treated with or without 
" phosphatase (10 U NEB lambda phosphatase / µg of lysate) for 1 h at 37°C.  Next, 
lysates were treated with 50, 500 or 5000 nM of caspase-3 and -7 for 1 h at 37°C 
followed by termination of the reaction by adding 6 µM of the irreversible caspase 
inhibitor z-VAD-fmk (Sigma).  Finally, samples previously left phosphorylated were then 
treated with " phosphatase as above and either further processed using TAILS for 
proteomic analysis, or 2 ! Laemmli buffer added for western blotting. 
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4.2.2 Sample preparation using TAILS 
TAILS was performed largely as described previously (16).  Briefly, caspase 
degradomes were diluted 1:1 in 8 M guanidine hydrochloride.  Cysteines were reduced 
by adding 5 mM DTT and incubated at 65°C for 1 hour and then alkylated by 
iodoacetamide treatment for 2 h at room temperature in the dark.  After quenching excess 
iodoacetamide with DTT, the pH was adjusted to 6.5 using 0.5 N HCl to prepare for 
dimethyl labeling of primary amines.  Samples were dimethylated by addition of 20 mM 
NaBH3CN and 40 mM 12CH2-formaldehyde (light) (Sigma) or 13CD2-formaldehyde 
(heavy) by reaction at 37°C overnight, followed by quenching with 100 mM Tris 
(tris(hydroxymethyl)aminomethane) (pH 6.8) for 4 hours.  Samples were mixed at this 
point and proteins were precipitated with cold methanol and acetone (8:1), washed 3! 
with methanol to remove excess label and amines, resuspended in 8 M guanidine 
hydrochloride and diluted 8-fold in 1 M HEPES (pH 8.0).  Trypsin (Promega) was added 
(1:100 trypsin:lysate (w/w)) and incubated overnight at 37°C, followed by a fresh trypsin 
addition (1:200) for another 4 hours.  Finally, internal tryptic peptides were reacted with 
HPG-ALDII polymer (Flintobox) to negatively select for protein N-termini and caspase-
generated, dimethylated neo N-termini.  Here, 2 mg of polymer and 20 mM NaBH3CN 
were added to 1 mg of lysate, the pH adjusted to 6.5 with HCl and the reaction incubated 
at 37°C overnight.  After quenching with 100 mM Tris (pH 6.8), negative selection of N-
termini was performed by filtering the polymer with a 10-kDa cutoff (the polymer is 
~80kDa) Microcon spin-filter as per the manufacturers instructions.  The N-terminome 
containing flow through was cleaned up on a C18 light Waters Sep-Pak by acidifying the 
sample in 0.1% formic acid, applying it to the column, washing with 0.1% formic acid, 
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and elution in 80% ACN / 0.5% formic acid.  Samples were then vacuum centrifuged and 
stored at -20°C until mass spectrometer analysis.    
 
4.2.3 Peptide Identification using Mass spectrometry  
The peptides are loaded onto a 2 cm long X 360 !m o.d. " 100 !m i.d. 
microcapillary fused silica precolumn packed with Magic 5 !m C18AQ resin (Michrom 
Biosciences, Inc.).   After sample loading, the precolumn is washed with 95% Solvent A 
(0.1% formic acid in water) /5% Solvent B (0.1% formic acid in Acetonitrile) for 20 min 
at a flow rate of 2 uL/min.  The precolumn is then connected to a 360 !m o.d. " 75 !m 
i.d. analytical column packed with 14 cm of 5 !m C18 resin constructed with an 
integrated electrospray emitter tip.   The peptides are eluted at a flow rate of 250 nL/min 
by increasing the percentage of solvent B to 40% with a Nano-Acquity HPLC solvent 
delivery system (Waters Corp.).  The LC system is directly connected through an 
electrospray ionization source interfaced to an LTQ Orbitrap Velos ion trap mass 
spectrometer (Thermo Electron Corp.).   The mass spectrometer is controlled by Xcalibur 
software (Thermo. ver. 2.1.0.1140) and operated in the data-dependent mode in which the 
initial MS scan recorded the mass to charge (m/z) ratios of ions over the range 400–2000.  
The 10 most abundant ions are automatically selected for subsequent collision-activated 
dissociation.  Each sample was run in duplicate.  Raw files were searched and quantified 
using Maxquant (17) version 1.2.2.5 using the Uniprot database (20 November, 2012). 
Cysteine residues were searched as a fixed modification of +57.0215 Da, oxidized 
methionine residues as a variable modification of +15.9949 Da and deamidated 
asparagine and glutamine residues as a variable modification of +0.9840. Light and heavy 
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dimethylation of peptide amino termini and lysine residues were set as variable 
modifications of +28.0313 Da and +34.0631 Da, respectively. Peptides were queried 
using Asp-C and Arg-C cleavage constraints with a maximum of two missed cleavages 
sites. The mass tolerances were 6 ppm for parent masses and 0.6 Da for fragment masses. 
The peptide false-discovery rate was set to 0.01.  A hit was defined as appearing in at 
least two runs.  There were 6 runs total – technical duplicates of 3 experiments.  When 
quantitative data was present in both runs of a technical duplicate, the geometric mean of 
the heavy:light ratio was taken. The weblogo of P1 Asp peptides was determined as 
previously described (18). 
 
4.2.4 Western Blotting 
 Samples were separated on SDS-PAGE gels and transferred to PVDF membrane 
using standard procedures.  Membranes were blocked with 5% BSA/TBST and probed 
overnight with primary antibodies in 1% BSA/TBST.  PKC!, MST1, MST3, Yap1 and 
Golgin-160 antibodies were all purchased from abcam.  Presenilin-1 antibodies were 
from Novus Biologicals, phospho-Histone H2B from Cellular Signaling and phospho-
EEF1D and phospho-EEF1B made as previously described (19). 
 
4.2.5 Peptide Synthesis 
Peptides were synthesized on resin by standard Fmoc-based peptide chemistry 
with an Automated Multiple Peptide Synthesizer (Intavis). Fmoc-Lys(Dinitrophenol)-OH 
(Bachem) was attached to the C terminus of each peptide, and peptides were capped with 
Fmoc-Trp-OH and biotin at the N-terminus. Phosphorylated peptides were generated 
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with Fmoc-Ser [Ser[PO(OBzl)-OH]-OH (AnaSpec).  Peptides were resuspended in 250 
mM HEPES (pH 7.5) and the pH adjusted to 7.5 with NaOH.  Peptide concentration was 
determined by OD 355 and identity was verified by MALDI-TOF. 
4.2.6 Caspase Assays 
Recombinant caspase-3 (Addgene plasmid number 11821 (20)), -7 (Addgene 
plasmid number 11825 (20)) and -8 (Addgene plasmid number 11827 (20)) were purified 
and their activity assessed by active site titration as described previously (21).  Caspase-3 
assays were performed with 200 nM caspase and 100 µM peptide at 37°C in 20 mM 
PIPES (pH 7.4), 100 mM NaCl, 5% sucrose, 0.1% CHAPS (w/v), and 5 mM DTT for 15 
minutes.  Caspase-7 assays were performed in the same buffer, but with 600 nM of 
caspase.  Caspase-8 reactions were performed with 100 nM caspasee-8 in 1 M sodium 
citrate and 35 mM NaH2PO4/Na2HPO4 (pH 7.4) at 37°C for 5 minutes.  Reactions were 
quenched by the addition of the irreversible caspase inhibitor z-VAD-fmk (Sigma), 
diluted 1 in 4 and emission read at 355 nm after excitation at 280 nm.  Fluorescence was 
measured on a Horiba fluorolog-3 spectrofluorometer (Supplemental figure 1A and B) or 
on a SpectraMax M5 fluorescence plate reader.  Reactions were performed in 
quadruplicate and an ANOVA (analysis of variance) and Tukey’s test used to compare 
means of phosphorylated peptides with their unphosphorylated counterparts.   
 
4.3 RESULTS 
4.3.1 Unbiased proteomic evaluation of phosphorylation-dependent regulation of 
caspase-mediated cleavage 
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 In an effort to characterize the interplay between phosphorylation and caspase-
mediated degradation, we applied a proteomics approach to identify bona fide, phospho-
regulated caspase substrates.  In our workflow, we first treated HeLa cells with okadaic 
acid to maximize phospho-site occupancy, and then treated lysates with or without ! 
phosphatase, followed by recombinant caspase-3 and -7 (Figure 4.1B).  Next, we utilized 
TAILS (terminal amino isotopic labeling of substrates) as a means for enriching the 
proteome for caspase substrates (Supplemental Figure 4.1) (13).  Here, caspase-degraded 
proteomes are isotopically labeled at N-terminal and lysine residues with heavy (+34) or 
light (+28) formaldehyde.  Trypsin digestion reveals internal peptide N-termini whose 
amine groups are reactive against an aldehyde-coupled, high molecular weight resin, 
whereas the amine groups of protein N-termini and caspase-generated N-termini remain 
inert due to blockage by dimethylation.  In this way, filtering the lysate through a 10K 
cut-off membrane that removes the reacted resin/internal tryptic peptide species allows 
the N-terminome to pass through enriches the N-terminome.  Performing LC-MS/MS 
analysis on an LTQ-Orbitrap identifies N-termini and, using spectra from MS1, produces 
a quantitative comparison between caspase degradomes from phosphorylated or 
dephosphorylated lysates.  Importantly, after digesting with caspases, the phosphorylated 
lysate was treated with phosphatase.  This permits a direct quantitative comparison 
between caspase substrates that may have a phosphorylation site that, if occupied, would 
alter retention time, mass, and undermine comparative analyses. 
Before analyzing proteomic samples with mass spectrometry, we first tested for the 
efficient dephosphorylation of cell extracts and for the presence of cleaved caspase 
substrates.  To this end, samples were analyzed at different points throughout the  
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Figure 4.1 – Workflow for the unbiased analysis of the integration of phosphorylation 
and caspase-mediated degradation.  (A) Depiction of the cleavage site nomenclature for 
proteases.  Caspases cleave the scissile bond between a P1 Asp and P1!.  (B) To measure 
the effect of phosphorylation on caspase cleavage in an unbiased fashion, we performed 
caspase assays on lysates that were treated with or without " phosphatase.  We predict 
that some substrates will be cleaved more after dephosphorylation (blue, [1]), others 
digested only in the context of the phospho-proteome (purple, [2]), and others still 
unaffected by treatment with phosphatase (red, [3]).  Samples are isotopically labeled 
using heavy or light dimethylation, followed by an N-terminomic strategy that enriches 
the proteome for neo-N-termini generated by caspase treatment (see Supplemental Figure 
4.1 for proteomic workflow). 
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workflow (Supplemental Figure 4.1) for EEF1D and EEF1B phosphorylation, and 
caspase cleavage of the previously identified substrate MST1 (22).  Lambda phosphatase 
treatment resulted in efficient dephosphorylation of phospho-EEF1D and phospho-
EEF1B, two abundant phospho-proteins with near stoichiometric phosphorylation 
(Supplemental Figure 4.2A, Lanes 1 and 2) (19).  Next these samples were treated with 
50 or 500 nM of caspase-3 and -7, which resulted in a dose-dependent decrease in full-
length MST1 (Supplemental Figure 4.2A, Lanes 3-6).  Finally, adding ! phosphatase to 
previously phosphorylated lysate abolished phospho-EEF1D and phospho-EEF1B 
antibody reactivity (Supplemental Figure 4.2A, Lane 3 and 5).  Further validating the 
efficiency of our enzyme treatments, we found that lysate phosphatase assays abolished 
reactivity of phospho-H2B antibodies when using extracts generated from nocodazole 
arrested cells, and increased migration speed of total Presenilin-1 levels, again indicative 
of complete dephosphorylation (Supplemental Figure 4.2B).  We also tested PKC", 
another known caspase substrate (23), for cleavage in lysates treated with a gradient of 
caspase-3 and -7 concentrations (Supplemental Figure 4.2C).  Proteolysis was again 
dose-dependent, and occurred with levels of caspases used previously in lysate cleavage 
assays (24).           
 Confident in our enzyme treatments of cell lysates, we generated TAILS samples 
from extracts treated with or without ! phosphatase and 50 or 500 nM of caspase-3 and -
7.  We identified and quantified 57 peptides with a P1 Asp, suggestive of caspase 
cleavage (Table 4.1).  Only peptides identified in at least two replicates (either biological 
or technical) were considered hits.  Weblogo analysis (18) of P1 Asp peptides generated a 
motif consistent with the consensus previously ascribed to caspase-3 and -7 (DEVD, 
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Figure 4.2A) (25).  Importantly, N-terminomic analysis of untreated Jurkat cells revealed 
that less than 5 % of protein N-termini contained a P1 Asp (26), reinforcing the 
conclusion that the majority of the P1 Asp peptides we identified are caspase substrates.  
Interestingly, a cursory analysis of the quanitified P1 Asp peptides revealed that the 
average peptide was cleaved 1.2 ! more when lysates were not treated with phosphatase, 
perhaps indicating a general positive influence of phosphorylation on caspase cleavage at 
the proteome level.  This skew is likely not due to labeling or sample bias, as P1 Asp 
quantitative data was normalized to the quantified protein N-termini isolated using 
TAILS (Supplemental Table 4.2), which should not change as a result of caspase 
treatment. 
 To validate the quantitative data returned from TAILS analysis, we repeated 
lysate dephosphorylation/caspase experiments, and probed for candidates using western 
blotting.  We focused on those substrates with consistent changes in cleavage across 
multiple replicates, and those either previously identified as caspase substrates or whose 
cleavage site matched the caspase-3 and -7 consensus motif (Figure 4.2C).  Using these 
criteria, we identified a previously reported caspase cleavage site on MST3 (AETD325) 
(27), and found that it was preferentially cleaved in phosphorylated lysates.  Indeed, 
western blotting analysis revealed a modest, but consistent change in the amount of full-
length MST3 that differed between " phosphatase treated and untreated lysates (Figure 
4.2B, upper panel).  In contrast, we found that Yap1 was preferentially cleaved when 
lysates were dephosphorylated.  Though cleavage of Yap1 at DEMD424 is not a known 
caspase site, the primary amino acid determinants do align with the caspase-3 and -7 
consensus motif, increasing our confidence that the site is a true positive.  Along these  
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Figure 4.2 – TAILS analysis reveals MST3, Yap1 and Golgin-160 as three validated 
candidates whose cleavage is regulated by phosphorylation.  (A) A weblogo analysis (18) 
of the 57 P1 Asp peptides identified by TAILS.  (B) HeLa lysates were treated identically 
to those samples prepared for N-terminomic analysis (see materials and methods), except 
were utilized for western blotting with antibodies directed against MST3, Yap1 or 
Golgin-160 as indicated.  Caspase-3 and -7 were used at concentrations of 0, 50, 500 and 
5000 nM.   (C) Caspase motif of TAILS hits validated in (B).  
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lines, treating lysates with caspase-3 and -7 resulted in a dose-dependent decrease of full-
length Yap-1, as well as the generation of smaller anti-Yap1 reactive bands (Figure 4.2B, 
middle panel).  Furthermore, full-length Yap1 was slightly more resistant to caspase 
cleavage when lysates were treated with ! phosphatase, and two degradation products 
were less abundant in the phosphatase treated samples which is also consistent with a 
protective role for phosphorylation (Figure 4.2B, arrow and arrowhead).  Conversely, 
another Yap1 reactive band (denoted with *) persisted only in samples treated with ! 
phosphatase, perhaps suggesting another caspase-site that is positively regulated by 
phosphorylation.  Though the presence of multiple caspase sites on Yap1 seems apparent, 
our western blot validation data is consistent with the TAILS quantitation.  Lastly, we 
found that Golgin-160 (referred to as GOLGA3 in Table 4.1) was also cleaved less in 
phosphorylated lysates at SEVD311 – a site previously identified as being targeted by 
caspase-3 and -7 in vitro and in response to diverse apoptotic stimuli (28,29).  Repeating 
lysate dephosphorylation and caspase assays, followed by measuring cleavage with 
western blotting were again consistent with the data returned from TAILS (Figure 2B, 
lower panel).  Here, in the phosphatase treated lysates, a more rapid conversion to the 
fully cleaved form is observed.  In contrast, an intermediate, slower migrating cleavage 
fragment remained even at the highest dose of caspase-3 and -7 (5 µM) in the 
phosphorylated lysates.  Caspase-3 and -7 can also cleave Golgin-160 at D59 and D139, 
and so our blots are consistent with the model that intermediate cleavage fragments of 
Golgin-160 have been processed at these other residues, but phosphorylation blocked 
proteolysis at SEVD311.  Ultimately, these data highlight novel mechanisms regulating 
the susceptibility of MST3, Yap1 and Golgin-160 to caspase cleavage.  
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4.3.2 Systematic characterization of the effect of phospho-Ser on caspase cleavage  
The finding that caspase cleavage of MST3, and other proteins from our TAILS 
analysis, were cleaved less after dephosphorylation prompted us to systematically 
evaluate the determinant properties of phospho-residues within the context of peptide 
substrates.  A number of anecdotal examples of phosphorylation regulating caspase 
cleavage of substrate peptides exist, but the determinant properties of phospho-residues 
on proteolysis have not been systematically or rigorously defined.  To address this 
question, we designed a phospho-scanning series of peptides that walked serine and 
phospho-serine from P5 – P4! within a caspase-3/-7 model sequence, and from P4 – P3! 
for a caspase-8 model sequence (Supplemental Table 4.3).  A broader series was used for 
caspase-3 and -7 due to the observation that primary amino acid specificity can extend 
beyond the canonical P4 – P1! residues for these caspases (15).  Peptides were 
synthesized with the FRET pair of tryptophan and lysine-DNP (2,4-dinitrophenol) at 
either termini.  When the peptide is intact, emission by tryptophan at 355 nm after 
excitation at 280 nm is quenched by DNP, which absorbs at 355 nm.  Following substrate 
cleavage, release of tryptophan from close proximity to DNP abolishes quenching, and 
permits reaction rates to be monitored by measuring tryptophan fluorescence at 355 nm.  
Indeed, caspase-3 and -7 reactions with a model peptide (see Supplemental Table 4.3 for 
sequence) maintained linearity through 15 minutes of reaction time, and were not cleaved 
when P1 was substituted with alanine (Supplemental Figure 4.3A, B).  Caspase-8 
reactions proceeded to completion more quickly, so shorter reaction times were used 
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below (Supplemental Figure 4.33C).  As expected, caspase-8 peptides were not cleaved 
when P1 was mutated from Asp to alanine. 
    The phospho- and non-phospho walking series produced essentially identical 
patterns when comparing caspase-3 and -7 – perhaps not surprising given their extensive 
sequence and consensus motif similarity (Figure 4.3) (25,30).  Analyzing the 
unphosphorylated series reveals that the relative effect of Ser throughout P5 – P4! is 
consistent with the literature.  For instance, substituting Ser for Asp at P4 decreased 
substrate conversion by a factor of 10 (data not shown) compared to the model, but 
became a measurable substrate when 5" more enzyme was used (see asterisk on Figure 
4.3).  Stennicke et al. (2000) also observed a large decrease in Kcat/Km when substituting 
P4 Asp to Ser for caspase-3 and -7 peptide substrates (31).  Similarly, substituting Ser for 
Glu at P3 decreased catalysis, which is consistent with a previous report (25).  
Discrepancies were seen at the P1! position, where Ser in place of Gly reduced cleavage 
by about one-half – an observation previously made for caspase-7, but not -3 (31).  
Because different models were used between our study and Stennicke et al. (2000), we 
cannot rule out peptide length or pairwise interactions at other sites as the cause for this 
discrepancy.  Nonetheless, our unphosphorylated peptides correlate well with the 
literature and validate our experimental system. 
 Analysis of the phospho-Ser peptides revealed an overall inhibitory effect on 
proteolysis (Figure 4.3).  Expectedly, phosphorylation at P2 (12) and P1! (32) abolished 
cleavage, but upon phosphatase treatment was almost completely rescued (Supplemental 
Figure 4.4).  As previously observed, phospho-P3 had little effect on proteolysis (32).  
During the course of our study, though, Dix et al. (2012) actually found that phospho-P3  
 146 
 
 
 
 
 
Figure 4.3 – Relative caspase-3 and -7 activities against phospho- and nonphosphorylated 
model peptides.  100 µM of internally quenched substrate peptides were reacted with 200 
nM of caspase-3 or 600 nM of caspase-7 for 15 minutes at 37°C and stopped by adding 
an excess of the irreversible caspase inhibitor zVAD-fmk.  P4 peptides, in which Ser or 
pSer is substituted for Asp, were not measurable at the above caspase concentrations, so 1 
µM of caspase-3 and 3 µM of caspase-7 were used (*).  Measuring the fluorescence at 
355 nm after excitation at 280 assessed activity.  Error bars represent the standard 
deviation of 4 reactions.  Means of the phosphorylated peptides and their 
unphosphorylated counterparts were compared using an ANOVA and Tukey’s test.  All 
pairs had P values < 0.001, except for the P3 pair, which had a P value > 0.05. 
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Figure 4.4 – Relative caspase-8 activity against phospho- and nonphosphorylated model 
peptides.  100 µM of internally quenched substrate peptides were reacted with 100 nM of 
caspase-8 for 5 minutes at 37°C and stopped by adding an excess of the irreversible 
caspase inhibitor zVAD-fmk.  Measuring the fluorescence at 355 nm after excitation at 
280 assessed activity.  Error bars represent the standard deviation of 4 reactions. Means 
of the phosphorylated peptides and their unphosphorylated counterparts were compared 
using an ANOVA and Tukey’s test.  All pairs had P values < 0.001, except for the P3 and 
P3! pair, which had P values > 0.05.!
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can have stimulatory or neutral effects on cleavage, depending on the peptide substrate 
used (14), representing a current inconsistency with part of the literature.  Interestingly, 
phospho-P2! almost completely abolished proteolysis, phospho-Ser at P5 and P3! reduced 
cleavage by about 2-3 fold and phospho-P4! was slightly inhibitory.  Overall, 
phosphorylated Ser has a negative effect on caspase-mediated cleavage, except at P3, in 
the context of our model peptide. 
 The effect of caspase-8 cleavage site phosphorylation showed similar trends to 
caspase-3 and -7.  Proteolysis was inhibited by phospho-Ser at P4, P2, P1! and P2! 
whereas P3 was unaffected by phosphorylation (Figure 4.4).  Again, this latter result is in 
contrast to a recent report by Dix et al. (2012), where phospho-P3 was exclusively a 
positive determinant for caspase-8 cleavage (14).  Also, compared to caspase-3 and -7, 
the effect of prime side phosphorylation on cleavage is less dramatic, as no significant 
difference between Ser-P3! and pSer-P3! was observed.  Taken together with our N-
terminomic data, the generally negative determinant properties of phospho-Ser suggests 
that phosphorylation-dependent promotion of proteolysis is controlled by factors outside 
of the primary amino acid sequence of the canonical caspase motif.  
 
4.4 DISCUSSION 
 The convergence of caspase and kinase signaling has recently been described as a 
major mechanism in the regulation of apoptosis (6,7).  One mode of kinase-mediated 
control of caspase signaling involves the phosphorylation of caspase substrates.  To 
identify proteins regulated in this manner, we utilized the N-terminomic strategy TAILS 
to monitor alterations in the caspase degradome of HeLa extracts with a native phospho-
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proteome versus lysates first treated with ! phosphatase.  In this way, we could for the 
first time measure caspase-mediated proteolytic events that were both positively and 
negatively regulated by phosphorylation in the context of a proteome.  Indeed, we 
identified and validated three proteins whose caspase cleavage is modulated by 
phosphorylation; Yap1 and Golgin-160 are degraded less when phosphorylated, whereas 
phosphorylation promotes cleavage of MST3. 
 By systematically evaluating the determinant properties of phospho-Ser within, or 
just proximal to, the canonical caspase consensus motif, we found that this post-
translational modification primarily inhibited cleavage.  Taken together with the 
observation that MST3 proteolysis is promoted by phosphorylation, this supports a model 
by which substrate phosphorylation can promote caspase motif accessibility or structure 
when occurring outside of the context of the motif itself.  In this sense, both factors play a 
role in the cleavage of protein substrates by caspases; elegant substrate engineering 
studies by Timmer and colleagues (2009) demonstrate that increasing the size of loops 
that contain the scissile bond promotes cleavage by two orders of magnitude (33).  These 
authors also made the surprising observation that caspases cleave scissile bonds located 
in "-helices almost as much as those in extended loops.  Interestingly, phosphorylation 
can have both stabilizing and destabilizing effects on "-helices (34) which may alter 
scissile bond accessibility.  
With respect to MST3, treating cells with the phosphatase inhibitor caliculyin A 
increases phosphorylation, activation, and structural reordering that alters its interaction 
partners (35).  Because our N-terminomic strategies used lysates from cells treated with 
okadaic acid, a phosphatase inhibitor that like calyculin A also inhibits PP1 and 2, one 
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interpretation of our data supports a model whereby MST3 is preferentially cleaved in its 
active form (35).  As well, MST3 is a pro-apoptotic kinase that exhibits increases in 
activity after the removal of its C-terminus by caspase cleavage (27).  One function of 
this hypothetical hierarchical layer of regulation is that phosphorylation and cleavage 
could provide graded levels of MST3 activity.  Precedence for promotion of cleavage by 
phosphorylation outside of the extended caspase motif has been observed.  
Phosphorylation of PKC! at Y332 promotes cleavage at D327 (36).  Indeed, Y332 is 
located at P5" and, based on our peptide studies, should be sufficiently far from the 
scissile bond to not interfere with catalysis. 
 Of the caspase substrates whose proteolysis is negatively regulated by 
phosphorylation, both Yap1 and Golgin-160 have phosphorylatable residues at positions 
that, when occupied with phosphate, were inhibitory towards cleavage of peptide 
substrates.  While the P4 Ser on Golgin-160 and P1" Thr on Yap1 have not been 
identified as phosphorylated in phospho-proteomics studies, their occupancy would be 
consistent with the cleavage patterns we observed on peptide substrates and in lysate 
cleavage assays.  At this point, we cannot rule out that remote phosphorylation sites 
reduce susceptibility to proteolysis much the same way that phosphorylation at S422 on 
Acinus-S reduces cleavage at D355 (8).  Interestingly, Golgin-160, and other members of 
the Golgi complex involved in structure and trafficking, are dismantled via caspase 
cleavage early in the apoptotic response (37).  Golgin-160 is cleaved at D59, D139 and, 
D311 – the site we identified – with purified caspases and in cells after diverse apoptotic 
stimuli (28).  In our validation studies, we inferred via the differential migration of 
Golgin-160 cleavage products, that two of these sites (D59 and D139) were cleaved in 
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phosphorylated lysates, but that proteolysis at SEVD311 was blocked by phosphorylation.  
Interestingly, in response to apoptotic signals initiating from death receptors or ER stress, 
non-cleavable forms of Golgin-160 can actually block apoptotic progression (29), though 
the effect of blocking each caspase site in isolation remains unknown.  Yap1 is another 
caspase target that we validated as having a cleavage site that is modulated by 
phosphorylation.  While DEMD424 has not previously been identified as a caspase 
cleavage site, ASTD111 is cleaved in Jurkat cells in response to apoptotic induction by 
TRAIL and staurosporine, perhaps resolving why we observed multiple cleavage 
products in our validation studies (38).  Furthermore, P3 and P2 of ASTD111 have 
previously been identified as phosphorylated in cells (39), again clarifying results from 
our western blots that indicated multiple cleavage products were differentially regulated 
between the phosphorylated and phosphatase treated lysates.  In terms of functionality, 
Yap1 is a transcriptional effector of the MST1 and 2 kinases (40), which themselves are 
also targeted by caspases and function in apoptotic progression (22,41).  Interestingly, 
MST1 and 2 contain previously identified phosphorylation sites at P1! and P3!, 
suggesting that caspase cleavage of multiple constituents of the same pathway are 
hierarchically regulated by phosphorylation (42).  As well, MST1 phosphorylation by 
Akt at T387, a site distant from the scissile bond, blocks cleavage (43), further 
implicating the control of proteolytic processing of this pathway as an important 
signaling event. 
One potential limitation of our approach relates to the high stoichiometry of 
caspase-site phosphorylation required for a difference in susceptibility to be measurable.  
In an effort to overcome this limitation, we treated cells with okadaic acid to increase 
! "#$!
phosphorylation site occupancy.  Similarly, the effect of phosphorylation on cleavage is 
not necessarily absolute, such as at P3!, for example.  To avoid complete digestion of 
proteins with phosphorylation sites at these residues, we used two different caspase 
concentrations.  Nonetheless, despite these caveats, we were able to uncover a number of 
modulated caspase substrates, and validated Yap1, MST3 and Golgin-160 as caspase 
targets that experience altered degradation in response to lysate dephosphorylation.  
Yap1, MST3 and Golgin-160 have roles in processes pertaining to cell survival, and so it 
is enticing to speculate that the functionality of modular cleavage mechanisms are 
physiologically relevant. 
As a logical extension to the unbiased investigation of the effect of 
phosphorylation on caspase-mediated degradation in the proteome, we were also 
interested in systematically evaluating the determinant properties of phosphorylated 
residues in the context of model substrate peptides.  Given the size and charge of 
phosphoryl residues, we speculated that phosphorylation may have effects outside of the 
canonical caspase motif and so extended our analysis outside of P4 – P1!.  Along these 
lines, even unmodified amino acids have exhibited determinant properties at P6, P5, P2! 
and P3! (15).  Furthermore, Dix et al. (2012) recently catalogued a large number of 
caspase sites with phosphorylated residues in this extended motif, though the precise 
effects of phosphorylated residues at many of these positions remain unknown  (14).  In 
systematically analyzing the positional effect of phospho-Ser on caspase cleavage, we 
found that phosphorylated residues outside the canonical caspase motif could indeed 
inhibit caspase-mediated cleavage.  Prime side (C-terminal of the scissile bond) 
determinants inhibited cleavage as far away as three residues from the scissile bond and 
! "#$!
the inhibitory capacity was inversely proportional to distance from the catalytic 
machinery.  This finding may be partly explained by previous observations made by 
Stennicke et al. (2000) (44).  Here, the authors show that negative determinants at P1! fail 
to stabilize the transition state.  Therefore, the bulky, highly charged nature of phospho-
Ser might act similarly, but with diminishing effect as it moves away from the catalytic 
machinery.   Evidence for an S5 binding site (that interacts with P5) on caspases has also 
recently become evident.  P5 residues can positively influence cleavage by caspase-3 
(45), and direct selectivity between caspase-3 and -7 (15), so we investigated the effect of 
phosphorylation at this position.  Inhibition is consistent with a preference for small non-
polar residues by caspase-3 (15).  The determinant properties of P5 on caspase-7 are less 
obvious, making the specific reasons for phospho-P5 more difficult to reconcile (15). 
Inhibitory effects at P4, P2 and P1! were consistent with the literature, but we did 
note a discrepancy at the P3 position.  Dix et al. (2012) found that phospho-P3 on 
substrate peptides was strictly a positive factor for caspase-8 cleavage, and either 
promotes or has no effect on caspase-3 mediated degradation (14), whereas like Toszer et 
al. (2003), we observed no effect at this site for both caspase-3 and -8 (46).  We cannot 
definitely explain this discordance, but can speculate that reaction conditions may have 
played a part.  First, that Dix et al. (2012) used enzyme:substrate ratios 10-100" greater 
than our own, and reaction times that were 20" longer, suggests that their enzymes were 
less stable.  As well, for caspase-8, we used the chaotropic agent sodium citrate, which 
promotes caspase activity by stabilizing the dimeric form (47).  Collectively, it is possible 
that the determinant properties of phospho-P3 may depend on reaction conditions that 
affect enzyme stability.  Another possibility includes the substrate peptides used; Dix and 
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colleagues (2012) tended towards longer peptides and those with sequences that differed 
from our model, suggesting that lengthier peptides or pairwise primary amino acid 
interactions could affect cleavage.  At the minimum, though, our mutual findings are 
consistent in that phospho-P3 does not inhibit cleavage. 
 In accordance with the literature, phospho-P2 and phospho-P1! were also 
inhibitory towards proteolysis (12,46).  Of note, however, was the measureable activity of 
caspase-8 against these peptides, whereas caspase-3 and -7 activity was not detected 
under the conditions used.  Furthermore, baseline levels of cleavage by caspase-8 for 
peptides phosphorylated at P2! and P4 were also above background, perhaps suggesting 
higher tolerance against the inhibitory effects of caspase-8 site phosphorylation.  Along 
these lines, the only known caspase-8 protein substrates negatively regulated by 
phosphorylation are phosphorylated at two sites within the cleavage motif; 
phosphorylation at P2 and P1! of caspase-3 blocks its cleavage by caspase-8 (12), and 
phospho-P2 and P2! prevent cleavage of Bid (9).  In this way, phosphorylation at 
multiple, slightly tolerated positions may function to grade cleavage and modulate the 
signaling output. 
In sum, we used two strategies to understand the interplay between caspase 
substrate phosphorylation and proteolysis.  As well as systematically characterizing the 
primary sequence determinant properties of phospho-Ser within peptide substrates, we 
also utilized an unbiased, N-terminomic approach to monitor caspase substrates that were 
regulated by phosphorylation in the context of the proteome.  Overall, we anticipate that 
efforts such as ours that disambiguate the hierarchical regulation of caspase substrate 
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phosphorylation and cleavage will improve our understanding of apoptotic signaling and 
undercover signaling pathways that control cell survival. 
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4.6 SUPPLEMENTAL FIGURES 
 
 
Supplemental Figure 4.1 – N-terminome enrichment using TAILS.  HeLa cell lysates 
were treated with or without ! phosphatase, followed by caspase treatment, and then 
dephosphorylation of the sample previously left phosphorylated.  Primary amines on 
protein N-termini and lysine residue are dimethylated using heavy (+34, open circles) or 
light (+28, black circles) formaldehyde.  Samples are pooled and trypsinized which 
exposes an amine on the N-terminus of the internal tryptic peptides.  These peptides are 
captured by reacting with an ~80 kDa, aldehyde substituted polymer.  Importantly, native 
protein N-termini and neo-N-termini generated by caspase cleavage are resistant to 
reaction with the polymer because their reactive amines have been blocked by 
dimethylation.  Enrichment of the N-terminome then occurs by negative selection via 
filtering away the reacted polymer using a 10-kDa cut-off spin column.  LC-MS/MS 
analysis of isotopically dimethylated peptides then allows comparative analysis between 
caspase degradomes of phosphorylated or dephosphorylated lysates.  Caspase substrates 
will be inferred by identifying those peptides with a P1 Asp.  In the event that there is no 
difference between caspase substrate proteolysis between phosphorylated and 
dephosphorylated samples, a peptide ratio of ~ 1:1 will be observed in MS1 [1].  Of 
interest are those peptide pairs that deviate from a 1:1 ratio [2].   
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Supplemental Figure 4.2 – Proof-of-principle for phosphatase and caspase treatment of 
HeLa cell extracts.  (A) Caspase degradomes were prepared as indicated in the materials 
and methods and samples taken after the first phosphatase treatment, and again after 
treatment with caspases and dephosphorylation of the previously ‘- phosphatase’ treated 
sample.  Samples were western blotted and probed first with antibodies directed against 
MST1 and then with phospho-EEF1D and phospho-EEF1B.  (B) Nocodazole-arrested 
HeLa cell lysates were dephosphorylated with ! phosphatase as indicated in materials 
and methods, western blotted and probed for phospho-EEF1D, phospho-EEF1B and 
phospho-H2B (left panel).  Similarly, HeLa extracts were ! phosphatase treated and 
western blotted for Presenilin-1 (right panel).  (C) HeLa lysates were treated with 0, 1, 
100 or 1000 nM of caspase-3 and -7 for 1 hour at 37°C and stopped by the addition of 2 " 
Laemmli buffer.  Reactions were western blotted with antibodies against PKC#. 
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Supplemental Figure 4.3 – Assessing the linearity of caspase reactions using model 
internally quenched caspase substrate peptides.  (A) The indicated amounts of caspase-3 
or -7 were reacted with model (DESD) or negative control uncleavable (DESA) peptides 
for 5 or 15 minutes at 37°C and stopped by adding an excess of the irreversible caspase 
inhibitor zVAD-fmk.  Tryptophan fluorescence was monitored by excitation at 280 nm 
and measuring emission at 355 nm on a fluorimeter.  (B) Assays were performed as in 
(A), except fluorescence was measured using a _ plate reader.  Error bars represent the 
standard deviation of 4 reactions. 
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Supplemental Figure 4.4 – Dephosphorylation of the phospho-P2 peptide substrates 
increases caspase cleavage.  Phosphorylated and non-phosphorylated P2 peptides were 
treated with or without ! phosphatase for 1 hour at 37°C.  After dephosphorylation, 100 
µM of peptide was used in reactions with 600 nM of caspase-7 for 15 minutes at 37°C.  
Reactions were stopped using the irreversible caspase inhibitor zVAD-fmk, followed by 
measuring tryptophan fluorescence at 355 nm after exciting at 280 nm.  Error bars 
represent the standard deviation of 4 reactions.  
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Supplemental Table 4.1.  List of P1 Asp peptides identified using TAILS.  Values in the 
experiment columns represent the ratio of peptide in phosphatase treated samples versus 
samples not treated with phosphatase.   
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Supplemental Table 4.2.  List of protein N-terminal peptides identified using TAILS.  
Values in the experiment columns represent the ratio of peptide in phosphatase treated 
samples versus samples not treated with phosphatase.  
! "#"!
 !
casp3/7 
substrate model biotin WGGDEVDGVAEG  K(DNP)  
  uncleavable biotin WGGDEVAGVAEG  K(DNP)  
P5 ser unphos biotin WGSDEVDGVAEG K(DNP)  
P4   biotin WGGSEVDGVAEG K(DNP)  
P3   biotin WGGDSVDGVAEG K(DNP)  
P2   biotin WGGDESDGVAEG  K(DNP)  
P1'   biotin WGGDEVDSVAEG  K(DNP)  
P2'   biotin WGGDEVDGSAEG K(DNP)  
P3'   biotin WGGDEVDGVSEG K(DNP)  
P4'   biotin WGGDEVDGVASG K(DNP)  
pP5 ser phos biotin WGpSDEVDGVAEG K(DNP)  
pP4   biotin WGGpSEVDGVAEG K(DNP)  
pP3   biotin WGGDpSVDGVAEG K(DNP)  
pP2   biotin WGGDEpSDGVAEG  K(DNP)  
pP1'   biotin WGGDEVDpSVAEG  K(DNP)  
pP2'   biotin WGGDEVDGpSAEG K(DNP)  
pP3'   biotin WGGDEVDGVpSEG K(DNP)  
pP4'   biotin WGGDEVDGVApSG K(DNP)  
casp8/9 
substrate model biotin WGIETDSGVG K(DNP)  
  uncleavable biotin WGIETASGVG K(DNP)  
P4 ser unphos biotin WGSETDSGVG K(DNP)  
P3   biotin WGISTDSGVG K(DNP)  
P2   biotin WGIESDSGVG K(DNP)  
P1'   biotin WGIETDSGVG K(DNP)  
P2'   biotin WGIETDSSVG K(DNP)  
P3'   biotin WGIETDSGSG K(DNP)  
pP4 ser phos biotin WGpSETDSGVG K(DNP)  
pP3   biotin WGIpSTDSGVG K(DNP)  
pP2   biotin WGIEpSDSGVG K(DNP)  
pP1'   biotin WGIETDpSGVG K(DNP)  
pP2'   biotin WGIETDSpSVG K(DNP)  
pP3'   biotin WGIETDSGpSG K(DNP)  
 
Supplemental Table 4.3.  List of peptides used for phospho-walking studies. !
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CHAPTER 5 – DISCUSSION 
 
5.1 GENERAL INTRODUCTION 
 The balance of cell survival and death is of crucial importance to maintaining 
total cell number homeostasis, and, if disturbed, can lead to proliferative diseases such as 
cancer (1,2).  Critical regulators governing these processes are two distinct families of 
enzymes – caspase, a family of pro-apoptotic proteases, and protein kinases, a group of 
phosphotransferases that transfer phosphate from ATP to hydroxyl residues on proteins.  
Interplay between these families is apparent, with an emerging role for the 
phosphorylation of caspase substrates to regulate susceptibility to proteolysis (3,4).  For a 
number of reasons, protein kinase CK2 has emerged as the kinase with perhaps the 
highest degree of integration within the caspase circuitry (4).  However, gaps in our 
knowledge still remain as to how this constitutively active kinase is regulated in disease, 
and what precise functions CK2 may perform when mis-regulated in cells.  Given the 
role of CK2 in apoptosis, the goal of this thesis was to utilize targeted strategies for 
identifying substrates that may promote anti-apoptotic signals emanating from mis-
regulated CK2.  
 
5.2 SUMMARY OF FINDINGS AND RESEARCH IMPACT 
5.2.1 Predicting and characterizing caspase-3 phosphorylation by CK2 
 In Chapter 2, we set out to identify CK2 substrates whose phosphorylation 
regulates their cleavage by caspases.  In large part, our efforts were guided by three 
characteristics of CK2.  First and foremost, CK2 is over-expressed in a number of human 
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cancers and contributes to tumourigenesis by, at least in part, blocking the efficient 
execution of apoptosis.  Second, CK2 phosphorylation is promoted by acidic primary 
amino acid determinants in the +1 and +3 position, and more generally, anywhere from -
2 to +7 (5-8).  Similarly, caspases by definition cleave at aspartic acid, but cleavage is 
also generally promoted by Asp at the P4 position, and Glu at P3 (9).  Finally, there is 
precedence for CK2 to regulate a number of other caspase substrates in this manner, such 
as Bid, Presenilin-1 and -2, and YY1 (10-14).  Collectively, these characteristics suggest 
that the crosstalk between caspases and CK2 may be underappreciated.  Furthermore, 
owing to the complex nature of this hierarchical regulatory mechanism, examples of 
phosphorylation-dependent blocking of caspase cleavage have only been found 
serendipitously.  Therefore, we sought to develop new strategies for identifying novel 
proteins regulated in this manner that could function by controlling apoptotic progression.  
To this end, we designed a peptide match program that positions a predicted CK2 
phosphorylation site adjacent to a putative caspase scissile bond, and, interestingly, 
identified caspase-3 itself.  Caspase-3 is an executioner caspase responsible for the 
majority of the caspase degradome (15), and only attains catalytic activity after cleavage 
by upstream initiator caspases (16,17).  Therefore, our guiding hypothesis was that 
phosphorylation by CK2 blocks activation of caspase-3, and could function, especially in 
the context of CK2 over-expression, to impede apoptotic progression.  We found that 
CK2 phosphorylates caspase-3 at the predicted S176, but also at T174.  These sites 
surround D175 – the scissile bond controlling caspase-3 activiation – and when 
phosphorylated, efficiently blocked cleavage by upstream initiators in vitro.  
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Interestingly, caspase-3 phosphorylation was specific for the free catalytic form of 
CK2, as reconstitution of the holoenzyme by CK2! addition to kinase assays 
dramatically inhibited phosphorylation.  Notably, of the hundreds of CK2 substrates that 
have been identified, only a handful are preferentially phosphorylated in the absence of 
the CK2! subunit (18,19).  In some ways, this may in part be due to the fact that not 
every identified substrate is tested with all forms of CK2.  Nevertheless, the function of 
free-catalytic CK2 in cells remain controversial, and so as well as characterizing the role 
that phospho-caspase-3 plays in apoptotic progression, the generation of phospho-
caspase-3 antibodies allowed us to for the first time systematically examine the catalytic 
activity of non-holoenzyme CK2 in living cells. 
Indeed, in chapter 3, we measured caspase-3 phosphorylation in HeLa cells by 
endogenous and ectopically expressed holoenzyme and free-catalytic CK2 (ie CK2"#-
HA, CK2"-HA, CK2"#-HA2/myc-CK2!2, and CK2"-HA2/myc-CK2!2).  By targeting 
caspase-3 to the nucleus with a NLS tag, or transfecting the non-NLS tagged version, 
which localizes to the cytoplasm, we could monitor two distinct pools of cellular CK2 for 
the free-catalytic form.  Interestingly, in these cells, it appeared that endogenous CK2 
was unable to phosphorylate caspase-3, even in the presence of okadaic acid, supporting 
the notion that cellular, catalytic CK2 is completely bound to CK2!.  However, over-
expression of individual catalytic subunits to levels that did not dramatically perturb total 
levels of CK2 activity (i.e. up to 2-fold) resulted in robust phosphorylation of caspase-3. 
These results also revealed a surprising preference for caspase-3 phosphorylation by 
CK2"#, which represents the first direct evidence for a CK2"# specific substrate in cells.  
Specificity was imparted by the catalytic domain in spite of extreme sequence identity in 
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this region, and sequence divergence at the N- and C-termini.  Curiously, our results 
support a mechanism in which CK2!" specificity was not the result of differential 
holoenzyme formation with endogenous CK2# in cells, and suggests that specificity is 
dictated by other positive or negative regulators controlling caspase-3 access to CK2!" 
and !, respectively.  Furthermore, these data have implications for the formation of the 
holoenzyme in cells, and suggest that at least a portion of newly expressed CK2! and !" 
are not immediately packaged into the holoenzyme.   
To avoid inappropriate caspase-3 activation, we used catalytically inactive 
caspase-3 when testing for phosphorylation in cells.  In an effort to study the functional 
effect of caspase-3 phosphorylation, we actually found that catalytically active caspase-3 
was phosphorylated much less in HeLa cells, preempting our efforts to understand the 
effect of phosphorylation on apoptotic progression.  Moving forward, a comprehensive 
evaluation of other model systems to identify endogenous, phosphorylated caspase-3 will 
be necessary to fully understand the role this modification might play in apoptosis (see 
section 5.3.2). 
Collectively, our results provide support for a model in which the complement of 
CK2 substrates phosphorylated in a given cell is dependent on the form of CK2 present.  
Evidence for this model is supported by the recent findings of Deshiere et al. (2012), as 
their work highlights that a shift to free-catalytic CK2 is driven by the loss of CK2# in 
various breast cancer patient samples (20). These authors propose that a distinct 
phenotype, namely the presence of EMT markers, mediated by increased free-catalytic 
CK2 is a direct consequence of reduced phosphorylation of SNAIL – a CK2 holoenzyme 
specific substrate – rather than increased phosphorylation of a free-catalytic specific 
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substrate.  Therefore, our work complements this study by providing evidence for the 
converse, that shifting the balance of CK2 from holoenzyme to the free-catalytic can 
result in phosphorylation of proteins targeted by this form.  Implications for these results 
have yet to be realized in disease models, but one obvious consequence of misbalanced 
CK2 expression is that the CK2-dependent phospho-proteome is modular and contingent 
upon the relative amount of each form of CK2 (Figure 5.1).  In this way, distinct cellular 
phenotypes may depend on the relative abundance of the different forms of CK2.  
 
5.2.2 Unbiased investigation of caspase substrate phosphorylation: identification of 
novel caspase targets with phospho-dependent changes in proteolysis  
As a logical extension of our peptide-match program, we devised an unbiased, N-
terminomic approach to look for differences in the caspase degradome between 
phosphorylated and dephosphorylated lysates.  N-terminomic strategies have been used 
extensively to identify caspase substrates in lysate cleavage assays (21), and from cells 
induced to undergo apoptosis (21-25), but never to directly identify substrates whose 
cleavage is modulated by phosphorylation.  Furthermore, our experimental design did not 
exclusively measure the effects of phosphorylations located adjacent to the scissile bond, 
but also considered distant phosphorylations or phospho-dependent interaction partners 
that may alter scissile bond accessibility through structural changes.  Finally, this 
approach is not limited to measuring only the effect of CK2 on the caspase degradome, 
but instead probes the native phospho-proteome generated by all active kinases in HeLa 
cells.  Notably, our dataset included cleavage events such as MST3 that were positively 
regulated by phosphorylation, and also examples of phosphorylations inhibitory to  
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Figure 5.1 – A Hypothetical representation of the functional redundancy and uniqueness 
of different forms of CK2.  Given the high sequence similarity between CK2! and !", 
undoubtedly these two isozymes control a number of redundant pathways.  However, our 
work supports a model stating that all forms of CK2 have unique cellular substrates.  
Misbalanced expression of these different forms in disease may lead to unique 
phenotypes that are dictated by the complement of available CK2 and CK2 substrates. 
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proteolysis, such as those on Yap1 and Golgin-160.  These data validated our strategy, 
and reinforced that native phosphorylations can have a range of effects on caspase 
cleavage. 
After observing that phosphorylation can both positively and negatively regulate 
caspase-mediated degradation, we set out to rigorously define the determinant properties 
of phosphorylation throughout the entire caspase motif.  In this sense, positional effects 
for amino acids have been thoroughly studied using peptide libraries and model 
substrates that interrogate P4-P1!, but that of phosphorylation has only been studied 
anecdotally.  To systematically uncover the effects of phosphorylation on caspase 
cleavage, we designed a series of model peptide substrates that walk phospho-Ser 
through the entirety of an extended caspase motif.  We found that phosphorylation was 
generally inhibitory from positions P5-P3! for caspase-3 and -7 and P4-P2! for caspase-8, 
but had no effect on any caspase at P3.  The overall negative effect of caspase substrate 
phosphorylation when located near the scissile bond suggests that when phosphorylation 
promotes cleavage, it is likely the result of altered substrate structure that promotes 
scissile bond accessibility.  As both caspase and phosphorylation databases continue to be 
populated with data from proteomics studies, we anticipate these determinant properties 
can be applied to guided, database mining approaches that seek to identify novel caspase 
substrates whereby phosphorylation regulates cleavage.  Collectively, our work 
contributes to a fundamental understanding of the effect of phosphorylation on cleavage, 
and, using modified N-terminomic approaches, identifies novel substrates regulated in 
this manner. 
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5.3 FUTURE DIRECTIONS 
5.3.1 Characterization of structural determinants that select for free-catalytic 
specificity 
 The ability of CK2! to modulate substrate specificity represents a regulatory 
mechanism long known to control CK2 in vitro, but the selective factors guiding this 
function remain enigmatic.  Primary amino acid sequence determinants surrounding the 
phospho-acceptor have been mapped to exosites on CK2 and found to interact with n+1, 
+3, +4 and +5 of the substrate (26).  Therefore, it follows that holoenzyme formation is 
not known to dramatically alter primary sequence determinants of substrate catalysis, but 
instead may impart unique, higher order structural features that interact with the substrate 
and guide phosphorylation.  Indeed, Leroy et al. (1997) proposed that an acidic loop of 
CK2! partially occludes the catalytic pocket of CK2" and blocks access of some 
substrates (27); notably, structures of the holoenzyme would later reveal the acidic loop 
of CK2! to make contact near the active site of CK2" (28).  For substrates inhibited by 
CK2!, treating the holoenzyme with polyamines is hypothesized to stimulate activity by 
competing CK2! away from the catalytic pocket of CK2, effectively opening the active 
site (27,29).  In spite of this, the catalytic parameters of most CK2 substrates are more 
favourable for the holoenzyme (18). 
In chapter 2, we present evidence for the identification of caspase-3 as a CK2 
substrate specific for the free-catalytic subunit.  Interestingly, preliminary work from our 
lab shows that caspase-8 is also phosphorylated by CK2 between the small and large 
subunits, at a site equivalent to T174 in caspase-3, but is paradoxically more efficiently 
phosphorylated by the holoenzyme (Kcat/Km of 0.42 versus 0.16, G. Vilk personal 
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communication).  Possible explanations for this discrepancy lie in differences in the 
structural environment of the area immediately surrounding the phospho-acceptors.  The 
most obvious variation is the length of the interdomain linker that contains the CK2 
phosphorylation sites; caspase-8 is 25 amino acids long versus 16 for caspase-3.  There is 
no structure of caspase-3 with an intact linker region, but its closest homologue caspase-7 
– which has a linker of the same length – has been solved, and so certain inferences can 
be made (30).  First, the region on caspase-7 that aligns with the CK2 phospho-acceptors 
is of low resolution, but, given its length, may be held closer to the catalytic groove of the 
enzyme than is the caspase-8 linker (Figure 5.2).  Also, a nearby loop – L4 – is actually 9 
amino acids longer on caspase-3 and -7, and may serve to occlude the bulkier CK2 
holoenzyme from gaining access to the phosphorylation site.  In contrast, the CK2 
phosphorylation on caspase-8 is further away from any protruding loops, and is stationed 
on an outer edge of the protein (Figure 5.2) (31).  Furthermore, caspase-3 exists as a 
dimer, whereas caspase-8 is monomeric under conditions utilized for our kinase assays 
(32,33); in this sense, dimeric versus monomeric form of caspases may also be 
responsible for selecting holoenzyme or free-catalytic CK2 specificity.  Generating 
caspase-3 and -8 chimeras that swap interdomain linkers and the L4 loop, or contain 
mutations at the dimer interface that reduce association (as has been shown for caspase-8 
(31)) may isolate structural determinants that select for holoenzyme versus catalytic 
specificity.  Ultimately, we predict that phospho-acceptors shielded from the holoenzyme 
are done so by restrictive, structural protrusions on the substrate.  In support of this 
model, there are no known peptide substrates preferentially phosphorylated by the  
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Figure 5.2 Structural alignment of caspase-7 and -8.  Caspase-7 (black, PDB: 1K86 (30)), 
the closest relative to caspase-3, and caspase-8 (off-white, PDB: 2K7Z (53)) are shown as 
a structural alignment (generated using Pymol).  The extended caspase-8 linker is shown 
in orange, with the phospho-acceptor of CK2 highlighted in red.  The linker of caspase-7 
is unstructured, but the ends are shown in pink.  The L4 loop of caspase-7 is shown in 
blue, whereas the L4 loop of caspase-8 is flexible and not defined in this structure.  Note: 
caspase-7 was crystallized as a dimer in PDB: 1K86, but the second chain was edited out 
for simplicity.  PDB: 2K7Z represents a solution structure of monomeric caspase-8.  
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catalytic subunit, suggesting that only structural factors can prevent phosphorylation by 
the holoenzyme.  
Conceptually related studies are underway in our lab, but employ engineered CK2 
substrate motifs positioned between two fluorophores.  This work has the added 
advantage of being easily translatable to cellular experiments that target biosensors to 
distinct cellular locations for the purpose of monitoring discrete CK2 populations in time 
and space.  In sum, a substrate engineering approach will permit a systematic 
characterization of the structural determinants guiding preferential phosphorylation by 
the free-catalytic subunit of CK2.  The closely related caspase-3 and -8 provide a unique 
model system with which to base these studies.  
 
5.3.2 Screening for endogenous phospho-caspase-3 in tissues and disease 
 The presence and function of free-catalytic CK2 in disease and physiology 
remains poorly understood.  Interestingly, there is evidence for tremendous variation of 
the relative levels of CK2 subunits in tissues from patients suffering from breast and head 
and neck cancer (20,34).  While the absolute levels in these instances remain unknown, 
the presence of undetectable CK2! and high levels of CK2" or "# suggests that CK2! 
may be sub-stoichiometric, which would inherently lead to cellular populations of free-
catalytic CK2.  Our demonstration that artificially generating free-catalytic CK2 by 
transfection, and the discovery that caspase-3 is phosphorylated under these conditions, 
suggests that the absolute and relative levels of regulatory and catalytic CK2 may control 
the CK2-dependent phospho-proteome.  It follows that the cancer promoting functions of 
CK2 could also depend on the complement of CK2 forms present in a cell, but to develop 
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this hypothesis we need to identify cell line models with misbalanced CK2 levels.  Based 
on its ability to discriminate between different forms of CK2, our phospho-caspase-3 
antibodies may accelerate the identification of such models. 
In terms of identifying caspase-3 phosphorylation in physiology, perhaps the 
tissue most likely exhibit this characteristic are mouse testes.  Here, protein expression of 
CK2!" was highest when compared to 7 other tissues (35).  Furthermore, the observation 
that CK2!" knockout mice experience a hyper-apoptotic phenotype in the testes suggests 
an anti-apoptotic role for CK2!" (36), which is consistent with a functional role for 
caspase-3 phosphorylation.  Extending beyond simply the relative levels of CK2 subunits 
as a key identifier for candidate tissuses, there is also immunohistochemical evidence for 
CK2!" and # to occupy distinct cellular locations in developing rat spermatocytes (37), 
suggesting that free-catalytic CK2!" is theoretically present.  Experiments aimed at 
isolating caspase-3 from mouse testes by immuno-precipitation, followed by western 
blotting with anti-phospho-caspase-3 antibodies, should provide a preliminary analysis of 
the presence of phospho-caspase-3 in this tissue.  Thematically related experiments can 
be envisaged for cancer cell lines with misbalanced expression of CK2 subunits such as 
those observed in breast (20) and head and neck cancer (34).  Furthermore, as repositories 
for cancer specimens continue to grow, misbalanced CK2 will be documented in other 
disease types. 
An alternative approach to understanding specific functions ascribed to individual 
forms of CK2 is to utilize strategies that aim to identify and measure other free-catalytic 
and holoenzyme specific CK2 substrates in cell lines or tissue samples.  To this end, we 
would take advantage of cell lysate kinase assays such as those described by Knight et al., 
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where isoform specific substrates of p38! and " were identified (38).  Here, the authors 
treat lysates with the irreversible kinase inhibitor FSBA, which reacts with the conserved, 
catalytic lysine residue of protein kinases, to inactivate all endogenous kinases.  Excess 
inhibitor is then washed away using low-molecular weight spin columns, followed by 
addition of the recombinant kinase of interest, in our case free-catalytic CK2 or 
holoenzyme, and ATP.  After kinase assays, samples are trypsinized, labeled with heavy 
or light dimethylation as in chapter 4, the phospho-peptides enriched and then identified 
and quantified using mass spectrometry (Figure 5.3).  Phospho-peptides unique to either 
treatment could then be applied to a number of downstream applications aimed at 
measuring the phosphorylation of these targets in different cell lines or tissues.  
One approach utilizes targeted proteomics strategies such as selected reaction 
monitoring (SRM) to identify tissues or cell lines with specific cohorts of CK2 substrates.  
SRM is a LC-MS approach that relies on the synthesis of phospho-peptides, followed by 
protocol development that seeks to establish transitions, or precursor/fragment pairs of 
ions (39).  By selectively measuring both the precursor and fragment, SRM is both 
extremely specific and sensitive.  The real power of SRM, though, comes from two 
important characteristics.  First, SRM is capable of measuring nearly hundreds of 
transitions in a single mass spectrometer run by toggling between the transitions of 
interest that occur at a predefined chromatography retention time (39).  Secondly, 
absolute quantification is made possible by spiking isotopically labeled, synthetic 
phospho-peptides into the phospho-proteome being analyzed (39).  Determining 
phosphorylation stoichiometry is even achievable when transitions of the synthesized, 
unphosphorylated peptides are measured (40).  Furthermore, as well as monitoring  
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Figure 5.3 – Systematic identification CK2 substrates specific for the holoenzyme or 
catalytic subunits.  To uncover substrates preferred by different forms of CK2, a 
proteomic approach that aims to identify CK2 substrates from cell lysates will be utilized.  
First, endogenous kinase present in the lysate will be inactivated using the irreversible 
kinase inhibitor FSBA, followed by its removal using low-molecular weight spin 
columns.  Free-catalytic CK2 (! and !") or both forms of the CK2 holoenzyme are then 
incubated with the lysate, ATP and the kinase cofactor Mg2+.  Sample trypsinization, 
phospho-peptide enrichment and peptide dimethylation are then followed by comparative 
phospho-proteomics.  Variations may also include the incorporation of a third label.  
Here, samples would be treated with phosphatase instead of CK2, to get a sense of the 
physiological relevance of the identified phosphorylation sites.  Similarly, phosphatase 
treatment could preclude kinase assays to maximize the unoccupied phospho-acceptors. 
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phosphorylation of CK2 substrates, we could also develop SRM protocols for peptides 
from the CK2 subunits themselves.  In this way, the ratio of catalytic:regulatory subunits 
of CK2 could be measured.  
By determing the phosphorylation status of CK2-form specific substrates, and the 
levels of CK2 subunits across different cell lines or tissue types, a number of important 
conclusions could be drawn.  First and foremost, by extending the measurement of free-
catalytic CK2 beyond caspase-3, stronger conclusions about the presence and function of 
free-catalytic CK2 can be achieved.   Secondly, the phosphorylation of free-catalytic 
substrates in the presence of excess CK2! would imply either an active, exclusion 
mechanism keeping the holoenzyme from forming, or the stimulation of holoenzyme by 
polyamines, which rescues holoenzyme inhibition of free-catalytic specific substrates.  
Lastly, the identification of cell lines with a spectrum of free-catalytic versus holoenzyme 
activity would provide a sound platform with which to study the differential functions of 
these different forms of CK2 in processes related to cell survival.  
    
5.3.3 Determining the effect of phosphorylation on cleavage of MST3, Golgin-160 
and Yap1 during apoptosis 
 Golgin-160, MST3 and Yap1 all have bona fide roles in either apoptotic 
progression or cell survivability, suggesting that cleavage modulation may alter cellular 
phenotypes.  Indeed, there is precedence in the literature for the inhibition of Golgin-160 
cleavage to block apoptotic progression; Golgin-160 non-cleavable mutants impair 
apoptosis in response to extrinsic stimuli and ER stress (41).  As well, MST3 is cleaved 
by caspases in cells, an event that activates MST3 and promotes apoptosis (42).  The 
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putative function of regulating Yap1 cleavage in apoptosis remains difficult to assess 
based on its pro- and anti-apoptotic functions (43-45).  However, the observation that 
upstream pathway constituents MST1 and 2 contain phosphorylation sites near their 
scissile bonds suggests that proteolytic control of this signaling pathway may be an 
important apoptotic checkpoint (45,46).   
A logical extension from our N-terminomic screen for caspase substrates whose 
cleavage is modulated by phosphorylation is to identify the phosphorylation sites that 
regulate Yap1, MST3 and Golgin-160 cleavage.  This would be performed by generating 
expression plasmids of the candidates that have non-phosphorylatable mutations, 
followed by lysate caspase cleavage assays that were treated with or without ! 
phosphatase.  In the case of Yap1 and Golgin-160, the presence of phospho-acceptors at 
positions within the caspase motif that inhibit cleavage when phosphorylated represent 
strong candidates with which to initially focus mutational studies.  Furthermore, the P4 
Ser on Golgin-160 (SEVD) actually strongly conforms to the CK2 motif.  Identifying 
MST3 phosphorylation sites that modulate cleavage should be more difficult because we 
have little basis for predicting phosphorylations that promote cleavage.  One area to start 
may be the region just outside extended caspase motif we studied (ie P5-P4") – phospho-
acceptors are present at P9-11, P6, P7" and P9".  These sites may function much the same 
way that P5" phosphorylation promotes PKC# cleavage (47).   
Once the phosphorylation sites responsible for altered cleavage kinetics in lysate 
caspase assays are identified, these mutants can be utilized to monitor kinetics after cells 
are induced to undergo apoptosis.  Because different apoptotic stimuli can cause different 
degradomes (25), a variety of apoptotic inducers will be utilized, such as TNF$/CHX to 
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activate the extrinsic pathway, and staurosporine, etoposide or thapsigargin to activate the 
intrinsic pathway.  Apoptotic time courses followed by western blotting will be used to 
identify differences in cleavage between wild-type and phospho-acceptor mutants.   
Finally, the function of altered cleavage kinetics will be determined using a 
variety of readouts after expression of wild-type, non-phosphorylatable and non-
cleavable mutants.  Blocking Golgin-160 processing has previously been shown to reduce 
PARP cleavage, a caspase-3 and -7 substrate, and reduce membrane blebbing associated 
with apoptosis (41).  Similarly, ectopic expression of the MST3 caspase cleaved fragment 
induces chromatin condensation, and so this readout could be used to measure altered 
cleavage of MST3 (42).  The function of Yap1 proteolysis is difficult to predict, as its 
cleavage has never been studied, but a good starting point would be assessing its better-
known functions after apoptotic induction.  For instance, Yap1 associates with p73 to 
modulate apoptotic gene expression after DNA damage (43,44).  As well, cytoplasmic 
sequestration is observed when phosphorylated by Lats1/2 or Akt (43,48), and so 
differences in localization between different mutants of Yap1 may be indicative of 
functionality in apoptosis. 
 
5.4 PERSPECTIVES 
 As highlighted in chapter 1, CK2 is a promising targeted therapeutic strategy for 
the treatment of various cancers.  Significant evidence exists for CK2 inhibition to 
specifically reduce cancer cell fitness, while not affecting normal cells (49-51).  
However, a unifying mechanism for the function of CK2 in disease is far from complete.  
The simplest demonstration of this is the dependence of phenotypic output after CK2 
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inhibition on the genetic background of the treated cells; apoptosis (51), autophagy (52) 
and different stages of cell cycle arrest have all been observed (51).  While other 
explanations are possible, these varied phenotypic responses suggest that distinct CK2 
functions may be differentially hijacked depending on the genetic context.  Work such as 
ours that attempts to define regulatory mechanisms, and context-specific 
phosphorylations will be crucial in instructing how to best target CK2 in disease.  In this 
way, successful pairing of CK2 inhibitors with other therapeutic strategies may depend 
on the active complement of the CK2 phospho-proteome, and may well vary amongst 
different genetic backgrounds, and the form of CK2 present.    
 
5.5 CONCLUSIONS 
 Protein phosphorylation and proteolysis are two important post-translational 
modifications implicated in nearly every aspect of cellular signaling.  Furthermore, the 
ability of phosphorylation to impact proteolytic events represents a hierarchical signaling 
mode that affords an extra level of regulation to cellular processes such as cell death.  
However, the complexity of this regulatory mechanism underscored the need for novel 
strategies to uncover the integration of kinase and caspase networks. 
 Collectively, this thesis demonstrates the utility of both predictive and proteomic 
strategies to identify caspase substrates whose cleavage is regulated by phosphorylation.  
Of the identified proteins, a number have functions in cell death and proliferative 
processes, and so these regulatory mechanisms may be important in apoptotic 
progression.  Of the kinases functioning within the caspase circuitry, CK2 may have the 
highest degree of integration.  Our work highlighting non-redundant functionality of the 
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!" catalytic subunit of CK2 is an important discovery that should accelerate the 
understanding of the regulation of CK2, and therefore how it can be targeted in disease. 
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